US10258503B2 - Ocular implant delivery device and method - Google Patents

Ocular implant delivery device and method Download PDF

Info

Publication number
US10258503B2
US10258503B2 US15/325,995 US201515325995A US10258503B2 US 10258503 B2 US10258503 B2 US 10258503B2 US 201515325995 A US201515325995 A US 201515325995A US 10258503 B2 US10258503 B2 US 10258503B2
Authority
US
United States
Prior art keywords
guide sleeve
implant
shell
central channel
syringe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US15/325,995
Other languages
English (en)
Other versions
US20170165108A1 (en
Inventor
Keith Bianchi
Bill Hartsig
Scott Nunn
Mukund Patel
Mark Sponsel
Lionel Vedrine
Ariel Waitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ForSight Vision4 Inc
Original Assignee
ForSight Vision4 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ForSight Vision4 Inc filed Critical ForSight Vision4 Inc
Priority to US15/325,995 priority Critical patent/US10258503B2/en
Assigned to FORSIGHT VISION4, INC. reassignment FORSIGHT VISION4, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GENENTECH, INC.
Assigned to PHILLIPS PLASTICS CORPORATION reassignment PHILLIPS PLASTICS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SPONSEL, Mark, BIANCHI, Keith, HARTSIG, Bill
Assigned to GENENTECH, INC. reassignment GENENTECH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NUNN, Scott, PATEL, MUKUND, WAITZ, Ariel, VEDRINE, LIONEL
Assigned to GENENTECH, INC. reassignment GENENTECH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PHILLIPS PLASTICS CORPORATION
Assigned to FORSIGHT VISION4, INC. reassignment FORSIGHT VISION4, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GENENTECH, INC.
Assigned to GENENTECH, INC. reassignment GENENTECH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PHILLIPS PLASTICS CORPORATION
Assigned to GENENTECH, INC. reassignment GENENTECH, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NUNN, Scott, PATEL, MUKUND, WAITZ, Ariel, VEDRINE, LIONEL
Assigned to PHILLIPS PLASTICS CORPORATION reassignment PHILLIPS PLASTICS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SPONSEL, Mark, BIANCHI, Keith, HARTSIG, Bill
Publication of US20170165108A1 publication Critical patent/US20170165108A1/en
Publication of US10258503B2 publication Critical patent/US10258503B2/en
Application granted granted Critical
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0026—Ophthalmic product dispenser attachments to facilitate positioning near the eye
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Definitions

  • the subject matter described herein relates to methods, systems and devices for holding, filling and/or delivering implantable drug delivery devices.
  • Implantable devices can be used to provide a therapeutic agent to one or more locations of a patient.
  • the implant may have a reservoir for holding therapeutic agent, and a structure to retain the implant at a desired location of the patient.
  • the agent can be released from the implant into the patient to provide a therapeutic benefit. After an amount of time, the amount of fluid released can be less than ideal, and the fluid of the implant may be replaced, refilled, or exchanged to provide additional amounts of therapeutic agent to extend the therapy.
  • a drug delivery device may be implanted into a patient's eye for the delivery of drug to the eye in treating eye disease.
  • Implementations of the present disclosure provide methods, systems and devices for filling implants with drug and for holding the implantable device during insertion of the device into the patient.
  • the methods, systems and devices provide for injection of a therapeutic agent into an implantable device prior to insertion.
  • the implantable device can be manufactured and provided to a clinic without a therapeutic agent, such that the therapeutic agent can be placed in the implantable device in the clinic prior to insertion.
  • an ocular implant system having an ocular implant having a retention structure and a reservoir sized and shaped to be inserted at least partially into an eye such that the implant can deliver a drug from the reservoir into the eye.
  • the system has a carrier member with a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell; and a guide sleeve removably attached within at least a first region of the central channel of the shell, the guide sleeve defining a proximal port into the central channel that is accessible from the proximal end of the shell.
  • the system includes an implant holder removably attached within at least a second region of the central channel of the shell adjacent to a distal end of the guide sleeve.
  • the implant holder has a pair of graspers adapted to releasably secure the implant at a distal end of the implant holder.
  • the system can further include a fill syringe sized and shaped to be inserted through the port into the central channel through the guide sleeve to fill the implant with one or more therapeutic agents.
  • the guide sleeve can simultaneously detach from the shell and attach to the fill syringe when the fill syringe is inserted into the central channel.
  • the guide sleeve can have at least one guide sleeve slot sized and shaped to receive a corresponding tab of the shell that projects into the at least one guide sleeve slot when the guide sleeve is positioned within the central channel. An edge of the guide sleeve slot can abut a distal end of the shell tab when in a locked first state.
  • the fill syringe can have a needle assembly having an outer surface, and optionally the fill syringe can be pre-filled with the one or more therapeutic agents. Insertion of the fill syringe through the guide sleeve positioned within the central channel can cause contact between the outer surface of the needle assembly and an inner surface of the shell tab urging the shell tab to flex outward away from the guide sleeve slot into an unlocked second state wherein the edge of the guide sleeve slot no longer abuts the distal end of the shell tab.
  • a region of the guide sleeve can have a u-shaped slot forming a guide sleeve tab.
  • the guide sleeve tab can have a free end that projects inwards towards a longitudinal axis of the guide sleeve positioned within the central channel.
  • the fill syringe can have a first portion having a first outer diameter and a second portion having a second outer diameter. The first portion can be located distal to the second portion and the first outer diameter can be larger than the second outer diameter.
  • Distal advancement of the fill syringe through the guide sleeve can cause the first portion of the fill syringe to abut against the free end of the guide sleeve tab and can urge the guide sleeve tab outward away from the longitudinal axis of the guide sleeve. Further distal advancement of the fill syringe through the guide sleeve can advance the first portion distal to the free end of the guide sleeve tab such that the free end flexes back inward toward the longitudinal axis and towards the smaller diameter second portion located proximal to the first portion.
  • the free end of the guide sleeve tab can abut a proximal ledge of the first portion locking the guide sleeve to the fill syringe.
  • the implant holder can have an interior configured to receive at least a portion of the needle assembly of the fill syringe.
  • the pair of graspers can extend substantially around the retention structure of the implant such that a fill port of the implant is available from within the interior of the implant holder.
  • a first grasper of the pair of graspers can have a first protrusion and a second grasper of the pair of graspers can have a second protrusion.
  • the first and second protrusions can be configured to be received within an indentation distal to the retention structure of the implant such that the retention structure is held within the interior of the implant holder and the reservoir extends distal to the implant holder.
  • the system can further include a handle member usable for inserting the implant into an eye.
  • the implant holder can be configured to interchangeably couple with the carrier member and the handle member.
  • the handle member can include an elongated proximal portion and a distal attachment portion.
  • the distal attachment portion can releasably attach to the implant holder.
  • the distal attachment portion of the handle member can be sized and shaped to be inserted through the central channel after the fill syringe and guide sleeve coupled to the fill syringe are removed from the shell.
  • the distal attachment portion can include a first arm and a second arm.
  • a proximal end region of the implant holder can have a pair of tabs formed by a pair of u-shaped slots.
  • Each of the pair of tabs can have a projection on its inner surface.
  • the first arm and the second arm can each have a recess on its outer surface.
  • Each of the recesses can be configured to receive the projections when the first and second arms are inserted through the interior of the implant holder.
  • the handle member can further include an actuator configured to detach the implant from the implant holder.
  • the pair of graspers When the actuator is in a first state, the pair of graspers can be positioned adjacent one another and surround the implant. When the actuator is in a second state, the pair of graspers can be urged away from one another and release the implant.
  • the actuator can include an actuator element, a spring-held slider member, and a pair of arms.
  • the actuator element can have a projection extending from a lower surface and have a ramped surface. Movement of the actuator element towards the upper surface of the handle can cause the ramped surface to slide against a corresponding ramped surface of the slider member urging the slider member in a proximal direction relative to the pair of arms.
  • the slider member can have a forked region interfaced with the pair of arms such that proximal movement of the slider member causes the pair of arms to open in a scissor-like movement. Opening the pair of arms can urge the pair of graspers away from one another releasing the implant held therebetween.
  • the central channel can terminate at a window extending through a distal end region of the shell.
  • the pair of graspers can secure the implant within the window.
  • the implant can have an elongate axis extending through a center of the implant from a proximal end to the distal end of the implant.
  • the elongate axis of the implant can be concentric with an elongate axis of the central channel.
  • a proximal end of the guide sleeve can be relatively flush with the proximal end of the shell.
  • a proximal end of the guide sleeve can extend a distance beyond the proximal end of the shell.
  • the proximal end of the guide sleeve can incorporate a gripping element.
  • the gripping element can have an ergonomic size and shape that facilitates grasping by a user.
  • the guide sleeve can have a generally cylindrical shape.
  • the guide sleeve can have a c-shaped cross section such that a first side of the guide sleeve is cylindrical and a second side of the guide sleeve is discontinuous. The discontinuous second side of the guide sleeve can align with the first side of the shell and the central channel.
  • an ocular implant handling system having a carrier member.
  • the carrier member has a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell.
  • the carrier member has a guide sleeve removably attached within at least a first region of the central channel of the shell.
  • the guide sleeve defines a proximal port into the central channel that is accessible from the proximal end of the shell.
  • the carrier member has an implant holder removably attached within at least a second region of the central channel of the shell adjacent to a distal end of the guide sleeve.
  • the implant holder has a pair of graspers adapted to releasably secure an implant at a distal end of the implant holder.
  • the handle member can be usable for inserting an implant into an eye.
  • the system can further include an ocular implant having a retention structure and a reservoir sized and shaped to be inserted at least partially into an eye such that the implant can deliver a drug from the reservoir into the eye.
  • the system can further include a fill syringe sized and shaped to be inserted through the port into the central channel through the guide sleeve.
  • the guide sleeve can simultaneously detach from the shell and attach to the fill syringe when the fill syringe is inserted into the central channel.
  • the guide sleeve can have at least one guide sleeve slot sized and shaped to receive a corresponding tab of the shell that projects into the at least one guide sleeve slot when the guide sleeve is positioned within the central channel. An edge of the guide sleeve slot can abut a distal end of the shell tab when in a locked first state.
  • the fill syringe can have a needle assembly having an outer surface. Insertion of the fill syringe through the guide sleeve positioned within the central channel can cause contact between the outer surface of the needle assembly and an inner surface of the shell tab urging the shell tab to flex outward away from the guide sleeve slot into an unlocked second state wherein the edge of the guide sleeve slot no longer abuts the distal end of the shell tab.
  • a region of the guide sleeve can have a u-shaped slot forming a guide sleeve tab.
  • the guide sleeve tab can have a free end that projects inwards towards a longitudinal axis of the guide sleeve positioned within the central channel.
  • the fill syringe can have a first portion having a first outer diameter and a second portion having a second outer diameter.
  • the first portion can be located distal to the second portion and the first outer diameter can be larger than the second outer diameter.
  • Distal advancement of the fill syringe through the guide sleeve can cause the first portion of the fill syringe to abut against the free end of the guide sleeve tab and urge the guide sleeve tab outward away from the longitudinal axis of the guide sleeve.
  • Further distal advancement of the fill syringe through the guide sleeve can advance the first portion distal to the free end of the guide sleeve tab such that the free end flexes back inward toward the longitudinal axis and towards the smaller diameter second portion located proximal to the first portion.
  • the free end of the guide sleeve tab can abut a proximal ledge of the first portion locking the guide sleeve to the fill syringe.
  • the implant holder can have an interior configured to receive at least a portion of the needle assembly of the fill syringe.
  • the pair of graspers can extend substantially around the retention structure of the implant such that a fill port of the implant is available from within the interior of the implant holder.
  • a first grasper of the pair of graspers can have a first protrusion and a second grasper of the pair of graspers can have a second protrusion.
  • the first and second protrusions can be configured to be received within an indentation distal to the retention structure of the implant such that the retention structure is held within the interior of the implant holder and the reservoir extends distal to the implant holder.
  • the handle member can include an elongated proximal portion and a distal attachment portion.
  • the distal attachment portion can releasably attach to the implant holder.
  • the distal attachment portion of the handle member can be sized and shaped to be inserted through the central channel after the fill syringe and guide sleeve coupled to the fill syringe are removed from the shell.
  • the distal attachment portion can include a first arm and a second arm.
  • a proximal end region of the implant holder can have a pair of tabs formed by a pair of u-shaped slots. Each of the pair of tabs can have a projection on its inner surface.
  • the first arm and the second arm can each have a recess on its outer surface.
  • Each of the recesses can be configured to receive the projections when the first and second arms are inserted through the interior of the implant holder.
  • the handle member can further include an actuator configured to detach the implant from the implant holder.
  • the pair of graspers When the actuator is in a first state, the pair of graspers can be positioned adjacent one another and surround the implant. When the actuator is in a second state, the pair of graspers can be urged away from one another and release the implant.
  • the actuator can include an actuator element, a spring-held slider member, and a pair of arms.
  • the actuator element can have a projection extending from a lower surface and having a ramped surface. Movement of the actuator element towards the upper surface of the handle can cause the ramped surface to slide against a corresponding ramped surface of the slider member urging the slider member in a proximal direction relative to the pair of arms.
  • the slider member can have a forked region interfaced with the pair of arms such that proximal movement of the slider member causes the pair of arms to open in a scissor-like movement. Opening the pair of arms can urge the pair of graspers away from one another releasing an implant held therebetween.
  • the central channel can terminate at a window extending through a distal end region of the shell.
  • the pair of graspers can secure an implant within the window.
  • An implant can have an elongate axis extending through a center of the implant from a proximal end to the distal end of the implant.
  • the elongate axis of the implant can be concentric with an elongate axis of the central channel.
  • a proximal end of the guide sleeve can be relatively flush with the proximal end of the shell.
  • a proximal end of the guide sleeve can extend a distance beyond the proximal end of the shell.
  • the proximal end of the guide sleeve can incorporate a gripping element.
  • the gripping element can have an ergonomic size and shape that facilitates grasping by a user.
  • the guide sleeve can have a generally cylindrical shape.
  • the guide sleeve can have a c-shaped cross section such that a first side of the guide sleeve is cylindrical and a second side of the guide sleeve is discontinuous. The discontinuous second side of the guide sleeve can align with the first side of the shell and the central channel.
  • an ocular implant handling and delivery system includes a handle member usable for inserting an ocular implant into an eye having an elongated proximal portion and a distal attachment portion.
  • the system includes a carrier member having a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell; and a guide sleeve removably attached within at least a first region of the central channel of the shell.
  • the guide sleeve defines a proximal port into the central channel that is accessible from the proximal end of the shell.
  • the system includes an implant holder removably attached within at least a second region of the central channel of the shell adjacent to a distal end of the guide sleeve.
  • the implant holder has a pair of graspers adapted to releasably secure the ocular implant at a distal end of the implant holder.
  • the implant holder is configured to interchangeably couple with the carrier member and the handle member.
  • the system can further include the ocular implant.
  • the ocular implant can include a retention structure and a reservoir sized and can be shaped to be inserted at least partially into an eye such that the ocular implant can deliver a drug from the reservoir into the eye.
  • an ocular implant handling and filling system in an interrelated aspect, includes a carrier member having a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell; and a guide sleeve removably attached within at least a first region of the central channel of the shell.
  • the guide sleeve defines a proximal port into the central channel that is accessible from the proximal end of the shell.
  • the system includes an implant holder removably attached within at least a second region of the central channel of the shell adjacent to a distal end of the guide sleeve.
  • the implant holder has a pair of graspers adapted to releasably secure an ocular implant at a distal end of the implant holder.
  • the system includes a fill syringe sized and shaped to be inserted through the port into the central channel through the guide sleeve.
  • the system can further includes the ocular implant having a retention structure and a reservoir sized and shaped to be inserted at least partially into an eye such that the implant can deliver a drug from the reservoir into the eye.
  • the system can further include a handle member usable for inserting an ocular implant into an eye.
  • the handle member can include an elongated proximal portion and a distal attachment portion.
  • the implant holder can be configured to interchangeably couple with the carrier member and the handle member.
  • a handling and filling system having a carrier member.
  • the carrier member includes a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell.
  • the carrier member includes a guide sleeve removably attached within at least a first region of the central channel of the shell.
  • the guide sleeve defines a proximal port into the central channel that is accessible from the proximal end of the shell.
  • the system includes an implant holder removably attached within at least a second region of the central channel of the shell adjacent to a distal end of the guide sleeve.
  • the implant holder has a pair of graspers adapted to releasably secure an implant at a distal end of the implant holder.
  • the system includes a fill syringe sized and shaped to be inserted through the port into the central channel through the guide sleeve.
  • the system includes a handle member usable for inserting the implant into an eye.
  • the handle member includes an elongated proximal portion and a distal attachment portion.
  • the implant holder is configured to interchangeably couple with the carrier member and the handle member.
  • the system can further include the ocular implant.
  • the ocular implant can include a retention structure and a reservoir sized and shaped to be inserted at least partially into an eye such that the ocular implant can deliver a drug from the reservoir into the eye.
  • a fill syringe sized and shaped to insert through a region of a carrier member holding an ocular implant.
  • the fill syringe is configured to inject one or more therapeutic agents from the fill syringe into a reservoir of the ocular implant.
  • the carrier member can include a shell having a central channel extending at least partially through the shell from a proximal end towards a distal end of the shell.
  • the carrier member can include a guide sleeve removably attached within at least a first region of the central channel of the shell.
  • the guide sleeve can define a proximal port into the central channel that is accessible from the proximal end of the shell.
  • a portion of the fill syringe can lock with a portion of the guide sleeve when the fill syringe is inserted through the central channel of the shell. Withdrawal of the fill syringe from the carrier member can remove the guide sleeve from the shell.
  • the fill syringe can be pre-filled with the one or more therapeutic agents.
  • FIG. 1A shows an implementation of a system for holding an ocular implant, filling the ocular implant with a drug and inserting the filled implant into an eye;
  • FIG. 1B shows an implementation of a system including a fill syringe
  • FIGS. 2A and 2B show front and back sides, respectively, of a carrier of the system of FIG. 1A ;
  • FIGS. 3A and 3B show front and back sides, respectively, of a shell of the system in FIG. 1A ;
  • FIGS. 4A and 4B show front and back sides, respectively, of a guide sleeve for use in a system
  • FIGS. 5A, 5B, and 5C show a front, back, and a proximal end view of the guide sleeve coupled to the shell;
  • FIG. 6 shows another implementation of a system with the fill syringe coupled to the carrier
  • FIG. 7 shows the system of FIG. 1B after the syringe has been used to fill the implant with drug and removed from the carrier;
  • FIGS. 8A and 8B shows an example of a mechanism for locking a guide sleeve to a carrier member
  • FIG. 9 shows a cross-sectional view of a locking mechanism that locks the guide sleeve to the carrier member
  • FIG. 10A shows an implementation of an implant holder for use with the system
  • FIG. 10B shows the implant holder of FIG. 10A holding an implant
  • FIGS. 10C, 10D, and 10E are front, side and back views, respectively of the implant holder of FIG. 10B ;
  • FIG. 10F is a partial cross-sectional view of the implant holder of FIG. 10B ;
  • FIG. 10G is a detail view of FIG. 10F taken along circle G;
  • FIG. 11 shows a handle member of the system ready to be inserted into the carrier member
  • FIG. 12 shows the handle member after it has been removed from the carrier member with the removable implant holder now attached to the handle member
  • FIG. 13 shows a locking mechanism that initially secures the implant holder to the carrier member
  • FIGS. 14A and 14B show the implant holder in a grasping state and a released state, respectively;
  • FIGS. 14C and 14D are partial views of the actuator system of the handle member
  • FIGS. 15A and 15B are cross-sectional views of a mechanism for releasing the implant from the implant holder.
  • Described herein are methods, devices and systems for easily, reproducibly, and safely filling an ocular implant with a material, such as a drug, and inserting the implant into a patient, such as a patient's eye.
  • a material such as a drug
  • systems described herein can be used with many devices used in locations other than the eye, such as in orthopedic, dental, intraluminal and transdermal locations.
  • the systems and methods described herein are well suited for use with many drug delivery devices, such as refillable diffusion based devices, and can be exceptionally well suited for diffusion devices having a porous drug release structure configured for extended release in which the porous structure inhibits flow of fluid during exchange.
  • FIG. 1A shows an implementation of a system for holding, filling, and/or delivering an ocular implant.
  • the system 100 can include an ocular implant handling system including an implant carrier member 105 and a handle member 115 .
  • the system 100 can further include a fill syringe 205 (see FIG. 1B ).
  • the fill syringe 205 can contain a therapeutic agent, such as a pre-filled syringe.
  • the carrier member 105 is sized and shaped to initially store an implant 110 prior to implantation of the implant 110 into the eye.
  • the fill syringe 205 can interface with the carrier member 105 to fill the implant 110 with a flowable material, such as a liquid drug or therapeutic agent.
  • the fill syringe 205 can interdigitate with the carrier member 105 holding the implant 110 and lock into a portion of the carrier member 105 (e.g. a guide sleeve), as will be described in more detail below.
  • the therapeutic agent or agents suitable for use with the implant 110 can vary, for example, as described in U.S. Pat. No. 8,623,395, entitled “Implantable Therapeutic Device,” which is incorporated here in its entirety.
  • the therapeutic agent can include one or more of a variety of active ingredients of the therapeutic agent, a formulation of the therapeutic agent, a commercially available formulation of the therapeutic agent, a physician prepared formulation of therapeutic agent, a pharmacist prepared formulation of the therapeutic agent, or a commercially available formulation of therapeutic agent having an excipient.
  • the therapeutic agent may be referred to with generic name or a trade name.
  • a portion of the carrier member 105 can guide and properly align a cannula or needle 210 of the syringe 205 with the fill port of the implant 110 .
  • the syringe 205 can interdigitate with this portion of the carrier member 105 and lock into it such that when the syringe 205 is removed, for example, after filling the implant 110 with the drug from the syringe 205 , the syringe 205 and this portion of the carrier member 105 locked onto the syringe can be withdrawn together.
  • the fill syringe 205 is removed (e.g.
  • the handle member 115 can be inserted into the carrier member 105 and used to remove the implant 110 from the carrier member 105 .
  • the handle member 115 and the carrier member 105 can interchangeably couple to the implant 110 .
  • the handle member 115 can be coupled to the carrier member 105 in a manner that attaches the implant 110 to the handle member 115 and detaches the implant 110 from the carrier member 105 .
  • the handle member 115 can then be used to position the implant 110 and insert the implant 110 into an eye.
  • the implant 110 can be pre-filled and stored within the carrier member 105 .
  • the implant 110 can be stored within the carrier member 105 while empty and filled prior to implantation in the eye, such as using a pre-filled syringe.
  • the implant 110 can be filled after implantation in the eye.
  • the implant 110 to be used with the system 100 described herein can include an internal reservoir.
  • the reservoir can be a rigid-walled reservoir having a fixed volume.
  • one or more of the reservoir walls can be configured to expand such that the reservoir volume changes depending on a fill status of the implant 110 .
  • the implant 110 can include a proximal retention structure 305 and an indentation 307 or narrowed region that is sized smaller than the retention structure 305 .
  • the indentation 307 can also be sized smaller than a shoulder region extending distal to the indentation 307 .
  • the indentation 307 can be sized to fit in an elongate incision.
  • the proximal retention structure 305 can include an access port having a penetrable region.
  • the proximal retention structure 305 can include or be covered by a penetrable barrier or septum structure such that the reservoir can be filled with a material.
  • One or more outlets can be positioned in fluid communication with the reservoir of the implant 110 such that therapeutic agent in the reservoir can be delivered to the patient.
  • the one or more outlets can incorporate a porous structure including one or more of many porous structures such as sintered material, openings in a non-permeable material, openings having a size and number to release therapeutic agent at an intended rate, a plurality of holes etched in a material, a semi-permeable membrane, or nano-channels, for example.
  • the configuration of implant 110 that can used with the system 100 described herein can vary.
  • the carrier member 105 can include a shell 101 and a guide sleeve 120 .
  • the guide sleeve 120 can be removably attached to the shell 101 .
  • the system 100 can also include an implant holder 125 configured to releaseably hold an ocular implant 110 within the shell 101 .
  • the implant holder 125 can be reversibly coupled to the shell 101 of the carrier member 105 .
  • implant holder 125 can be an interchangeable element that can be coupled to the carrier member 105 , for example prior to filling with a syringe 205 , and can be released from the carrier member 105 , for example after filling with a syringe 205 and prior to implantation in a patient using a delivery tool.
  • the implant holder 125 can be interchangeably coupled with the carrier member and the delivery tool.
  • the shell 101 of the carrier member 105 can include a central channel 103 extending at least partially through an upper surface of a first side, such as its front side 107 , from a proximal end 108 of the carrier member 105 towards a distal end region 109 of the carrier member 105 along a longitudinal axis.
  • the central channel 103 can terminate at an opening or window 111 extending through a distal end region 109 of the shell 101 .
  • the implant 110 can be positioned by the implant holder 125 within the window 111 .
  • the shell 101 of the carrier member 105 can be generally ergonomically shaped such that a user can hold the carrier member 105 in one hand positioned around the underside of the carrier member 105 .
  • the central channel 103 can be available and readily visible on the front side 107 of the carrier member 105 .
  • the shell 101 of the carrier member 105 can include one or more textured regions 112 or indentations on its external surface to improve a user's grip on the carrier member 105 during use.
  • the implant 110 can have an elongate axis extending through a center of the implant 110 from the proximal-most end to the distal-most end of the implant 110 .
  • the system 100 (and/or each of the components of the system) can also have an elongate axis that is concentric with the elongate axis of the implant 110 forming a longitudinal axis A with which each of the components of the system 100 are substantially aligned.
  • the elongate axis of the implant 110 can be aligned substantially with the longitudinal axis A of the system and the syringe 205 can be inserted substantially along the longitudinal axis A such that the needle 211 penetrates an upper surface of the implant 110 .
  • the syringe 205 can interdigitate within the central channel 103 along the longitudinal axis A or, in other implementations, can be inserted at an angle to the longitudinal axis A.
  • the carrier member 105 can include the guide sleeve 120 that can be removably attached within at least a region of the slot of the shell 101 .
  • the guide sleeve 120 can define a proximal port 113 into the central channel 103 of the shell 101 that allows for access to the slot from a proximal end of the shell 101 .
  • the guide sleeve 120 can help to ensure proper alignment between the syringe 205 and the implant 110 such that a needle 211 of the syringe 205 inserts through a septum or fill port of the implant 110 .
  • the guide sleeve 120 can provide guiding alignment during insertion of the syringe 205 through the port 113 into the central channel 103 towards the implant 110 mounted within the implant holder 125 of the carrier member 105 .
  • the configuration of the guide sleeve 120 can vary.
  • the guide sleeve 120 can have a length such that it extends a distance between the proximal end 108 of the shell 101 or central channel 103 and a distal region of the central channel 103 .
  • the guide sleeve 120 can be relatively flush with a proximal end 108 of the shell 101 (see FIGS. 2A and 2B ) or the guide sleeve 120 can extend a distance beyond the proximal end 108 of the shell 101 , for example, as shown in FIG. 1A-1B .
  • the guide sleeve 120 can incorporate a gripping element 121 .
  • the gripping element 121 of the guide sleeve 120 may have an ergonomic size and shape that facilitates it being grasped by a user, such as between the fingers of a user's hand as will be described in more detail below.
  • the guide sleeve 120 can have a generally cylindrical shape.
  • the guide sleeve 120 can be a generally cylindrical element having an overall c-shaped cross section such that the underside or back side of the guide sleeve 120 is cylindrical and the front side of the guide sleeve 120 is slotted or discontinuous (see FIGS. 4A-4B and also FIG. 5C ).
  • the cylindrical lower surface of the guide sleeve 120 can abut a lower portion 104 of the shell 101 and the discontinuous portion of the guide sleeve 120 can align with the upper surface of the front side 107 of the shell 101 .
  • the syringe 205 can have a body sized and shaped to be inserted into the central channel 103 of the shell 101 of the carrier member 105 via the port 113 such that a needle 211 of a needle assembly 210 of the syringe 205 can be inserted into the implant 110 mounted via the implant holder 125 on the carrier member 105 .
  • the syringe 205 can fill the implant 110 with a liquid drug or any other liquid prior to inserting the implant 110 into the eye.
  • the syringe 205 can have any of a variety of configurations as known in the art.
  • the syringe 205 can include a reservoir 215 that may be pre-filled with a fluid drug or any other fluid.
  • the reservoir 215 can include a proximal opening configured to receive a mechanism for expelling the fluid from the reservoir 215 through a distal opening of the reservoir 215 .
  • the mechanism for expelling the fluid from the reservoir 215 can be a plunger 225 including a piston rod 230 terminating at a piston head 235 .
  • the piston head 235 can be configured to contact the liquid to be injected from the reservoir 215 and maintain a seal as the plunger 225 is displaced distally within the reservoir 215 .
  • a stop element can be incorporated that prevents withdrawal of the piston rod 230 or piston head 235 through the proximal opening.
  • a proximal end of the syringe 205 can include a flange 245 that can aid in the advancement of the plunger 225 within the reservoir 215 as is known in the art.
  • a user can apply a force against an upper surface of the flange 245 (e.g. with the user's thumb) and apply a force against a lower surface of portion 250 (e.g. with a user's finger) therein applying a squeezing pressure to the syringe 205 engaged with the carrier member 105 .
  • the distal opening of the reservoir 215 can be in fluid communication with a needle assembly 210 coupled to the syringe by a luer 255 (see FIG. 1B and FIG. 9 ).
  • the needle assembly 210 can include a needle 211 and optionally a needle limiter 212 positioned around the needle 211 .
  • the needle limiter 212 can have a length such that a distal-most tip of the needle 211 extends only a short distance beyond the needle limiter 212 to prevent penetration of the needle 211 within the implant 110 beyond that short distance so as not to damage the implant 110 during filling.
  • the needle limiter 212 can abut an internal region of the implant holder 125 or an upper surface of the implant 110 preventing the needle 211 from penetrating the implant 110 beyond a desired depth.
  • the syringe 205 can include a needle cap configured to cover the needle 211 and needle limiter 212 .
  • the needle assembly 210 may be integrally formed with the syringe 205 or the needle assembly 210 may be detachable from the syringe 205 .
  • the guide sleeve 120 can be removably attached from within the central channel 103 of the shell 101 .
  • the shell 101 and/or the guide sleeve 120 can include a locking mechanism that reversibly secures the guide sleeve 120 to the shell 101 .
  • the locking mechanism can be released, for example, upon insertion of the syringe 205 as will be described in more detail below. After the syringe 205 has been inserted into the guide sleeve 120 positioned within the central channel 103 of the shell 101 such as to inject drug into the implant 110 , the locking mechanism between the guide sleeve 120 and the shell 101 can unlock.
  • the guide sleeve 120 can release from the shell 101 and lock onto the syringe 205 such that both the guide sleeve 120 and the syringe 205 can be removed from the shell 101 upon withdrawal of the syringe 205 from the implant 110 .
  • the locking mechanism can simultaneously release the guide sleeve 120 from the shell 101 and lock the guide sleeve 120 onto a region of the syringe 205 .
  • the locking mechanism holding the guide sleeve 120 onto the syringe 205 can be activated or locked and the locking mechanism locking the guide sleeve 120 to the shell 101 can be deactivated or unlocked.
  • the respective locking mechanisms can activate/deactivate in a simultaneous or step-wise manner.
  • FIG. 6 shows an implementation of the system 100 with the syringe 205 inserted into the carrier 105 .
  • FIG. 7 shows an implementation of the system 100 after the syringe 205 has been used to fill the implant 110 and the syringe 205 has been decoupled from the carrier member 105 .
  • the guide sleeve 120 is shown detached from the carrier member 105 and is now attached to the syringe 205 . It should be appreciated that unlocking or detaching the guide sleeve 120 from the carrier member 105 is not dependent upon filling the implant 110 .
  • the locking mechanism between the shell 101 and the guide sleeve 120 can include one or more corresponding slots and tabs providing a fixed, but reversible coupling between the shell 101 and the guide sleeve 120 .
  • the guide sleeve 120 can include one or more slots 122 having a size and shape configured to accept tabs 405 of the shell 101 such that the tabs 405 reversibly insert through the slots 122 when the guide sleeve 120 is positioned within the central channel 103 of the shell 101 .
  • the slots 122 can be located on opposing sides of the guide sleeve 120 .
  • the guide sleeve 120 can also include one or more tabs 123 formed by a u-shaped slot 126 through a thickness of the guide sleeve 120 . It should be appreciated that tabs 405 as well as tabs 123 can have a degree of flexibility such that they can move slightly with respect to the longitudinal axis A of the system to provide for reversible attachment between the guide sleeve 120 and the shell 101 as well as between the guide sleeve 120 and the syringe 205 , which will be described in more detail below.
  • FIGS. 3A-3B, 4A-4B and also FIGS. 8A-8B show an implementation of a locking mechanism that initially locks the guide sleeve 120 to the shell 101 of the carrier member 105 .
  • the shell 101 can include one or more tabs 405 configured to insert through one or more corresponding slots 122 in the guide sleeve 120 .
  • the tabs 405 are shown in a first state that locks the guide sleeve 120 to the shell 101 of the carrier member 105 .
  • the flexible tabs 405 can extend through the corresponding slots 122 in the guide sleeve 120 preventing withdrawal of the guide sleeve 120 in a proximal direction along arrow P.
  • FIG. 8B shows a syringe 205 inserted distally into the guide sleeve 120 such that an outer surface of the needle assembly 210 of the syringe 205 presses against an inner surface of the flexible tabs 405 urging them in outward direction.
  • the proximal end of the tabs 405 can be ramped such that the outer surface of the needle assembly 210 can smoothly press against and slide along the inner surface of the tabs 405 as the syringe 205 is urged in a distal direction along arrow D.
  • the tabs 405 can be urged back out the slots 122 in the guide sleeve 120 releasing the locking engagement between the slots 122 of the guide sleeve 120 and the tabs 405 of the shell 101 .
  • the edge 124 of the slot 122 may no longer abut the distal edge 408 of the tab 405 .
  • This same act of inserting the syringe 205 distally through the guide sleeve 120 releasing the locked engagement between the guide sleeve 120 and the shell 101 can also cause the guide sleeve 120 to lock onto a portion of the syringe 205 .
  • the one or more tabs 123 formed by the u-shaped slot 126 through a thickness of the guide sleeve 120 for example, in the cylindrical underside of the guide sleeve 120 (see FIG. 4B and also FIG. 9 ).
  • the tab 123 on the guide sleeve 120 can flex inward and outward relative to a longitudinal axis A of the guide sleeve 120 to capture a corresponding portion of the syringe 205 .
  • a free end 128 of the tab 123 can be angled or curved such that it projects inward towards the longitudinal axis of the guide sleeve 120 , or have a feature that encroaches within the interior of the sleeve 120 .
  • the flexible tab 123 of the guide sleeve 120 can capture the corresponding portion of the syringe 205 preventing the syringe 205 from being detached from the carrier member 105 without the guide sleeve 120 being coupled to the syringe 205 .
  • the guide sleeve 120 can include an inner diameter configured to receive the outer diameter of the syringe 205 such that the syringe 205 can be inserted through the guide sleeve 120 to inject drug into the implant 110 mounted within the implant holder 125 located distal to the guide sleeve 120 (see FIG. 9 ).
  • the free end 128 of the flexible tab 123 of the guide sleeve 120 projecting inward towards the central longitudinal axis A of the system 100 .
  • the syringe 205 can urge the flexible tab 123 outward away from the central longitudinal axis A as the syringe 205 is inserted through the guide sleeve 120 .
  • a distal region of the syringe 205 can include a first portion 206 having a first outer diameter and a second portion 208 having a second outer diameter. The first portion 206 can be located distally to the second portion 208 and the first outer diameter can be larger than the second outer diameter.
  • the outer diameter of the first portion 206 can abut the free end 128 of the tab 123 urging the tab 123 outward. Once the first portion 206 is advanced distal to the tab 123 , the free end 128 can flex back inward towards the longitudinal axis A and towards the smaller diameter second portion 208 located proximal to the first portion 206 .
  • the first portion 206 can have a proximal ledge 209 such that if the syringe 205 is withdrawn in a proximal direction, the free end 128 of the tab 123 can abut the proximal ledge 209 and cause the now-released guide sleeve 120 to withdraw along with the syringe 205 .
  • an implant holder 125 can be removably attached within at least a region of the central channel 103 of the shell 101 .
  • the implant holder 125 can be positioned such that an interior 901 of the implant holder 125 is coaxial with the central channel 103 of the carrier member 105 and the guide sleeve 120 (see FIG. 2A ).
  • a proximal end 902 of the implant holder 125 can lie adjacent to the distal end of the guide sleeve 120 and a distal end 903 of the implant holder 125 can extend beyond the central channel 103 into the window 111 .
  • the interior 901 of the implant holder 125 can be configured to receive at least a portion of the needle assembly 210 of the syringe 205 (see FIG. 6 ), as will be described in more detail below.
  • the implant holder 125 can include a pair of moveable mating graspers 905 a , 905 b configured to releasably secure the implant 110 to the carrier member 105 .
  • the implant 110 can include a proximal retention structure 305 that can include an indentation 307 dimensioned to receive first protrusion 907 a of a first grasper 905 a and a second protrusion 907 b of a second grasper 905 b to hold the implant 110 therebetween.
  • the protrusions 907 a , 907 b can be shaped in a variety of ways to engage the implant 110 , including lentoid, oval, elliptical, or circular structures.
  • the protrusions 907 a , 907 b can include a structure similar to the shape profile or outer contour or corresponding geometry of the indentation of the implant 110 .
  • first protrusion 907 a on the first grasper 905 a can include a proximal surface 910 a to engage a region of the distal surface 306 a of the retention structure 305
  • second protrusion 907 b on the second grasper 905 b can include a proximal surface 910 b to engage another region of the distal surface 306 b of the retention structure 305 .
  • the first grasper 905 a can be urged toward the second grasper 905 b to slide the first protrusion 907 a and the second protrusion 907 b into the indentation 307 of the retention structure 305 such that the proximal surfaces 910 a , 910 b engage the distal surfaces 306 a , 306 b .
  • the graspers 905 a , 905 b can extend substantially around a portion of the retention structure 305 of the implant 110 to hold the implant 110 .
  • the septum or fill port of the implant 110 can be available within the interior 901 of the implant holder 125 and the body of the implant 110 can extend beyond the implant holder 125 .
  • the implant 110 can be held by the implant holder 125 such that a longitudinal axis of the implant 110 is aligned substantially concentric or coaxial with the longitudinal axis A of the system 100 .
  • the syringe needle 211 can be inserted coaxially along the axis A of the implant 110 such that the needle 211 of the syringe 205 is advanced along the axis A toward the proximal end of the implant 110 .
  • the needle 211 of the syringe 205 can penetrate the fill port until a needle stop 212 contacts the proximal surface 910 of the graspers 905 or a proximal end of the implant 110 preventing further penetration of the needle 211 .
  • the interior 901 of the implant holder 125 as well as the guide sleeve 120 can further aid in aligning the syringe 205 and the needle 211 with the implant 110 and with the longitudinal axis A.
  • the implant holder 125 can additionally incorporate an opening into the interior 901 such that a needle can be inserted at an angle to the longitudinal axis A.
  • the implant holder 125 can be an interchangeable element that can lock in an alternating fashion with different portions of the system 100 , such as the shell 101 of the carrier 105 and a portion of the handle member 115 .
  • the proximal end 902 of the implant holder 125 can be reversibly coupled to a region of the shell 101 such as within the central channel 103 by a locking mechanism.
  • the locking mechanism can be configured to unlock the implant holder 125 from the shell 101 and then lock the implant holder 125 onto the handle member 115 once the handle member 115 is inserted into the carrier member 105 , which is described in more detail below.
  • the implant holder 125 can be attached to the region of the shell 101 and then attached to the handle member 115 upon release from the shell 101 .
  • the locking mechanism can include an indentation 912 near a proximal end 902 of the implant holder 125 configured to receive a correspondingly shaped element 410 of the shell 101 (see FIG. 3A and also FIG. 13 ).
  • the indentation 912 can have smooth edges such that the implant holder 125 can be removed from the element 410 , as will be described in more detail below.
  • the locking mechanism can also include a tab 914 formed by a u-shaped slot 916 located adjacent the indentation 912 , such as just distal to the indentation 912 .
  • the tab 914 can include a projection 918 on its inner surface (see FIG. 10F ) configured to engage with a correspondingly shaped recess 505 within a region of the handle member 115 when the handle member 115 is inserted through the interior 901 of the implant holder 125 as will be described in more detail below.
  • the system 100 can also include the handle member 115 .
  • the handle member 115 can be attached to the implant holder 125 holding the implant 110 (see FIGS. 11 and 12 ).
  • the implant holder 125 can be interchangeably attached to the shell 101 of the carrier 105 and the handle member 115 .
  • Insertion of the handle member 115 into the carrier member 105 can release the attachment of the implant holder 125 with the shell 101 and cause the attachment between the implant holder 125 and the handle member 115 such that the implant holder 125 can be removed from the carrier 105 and the handle member 115 can be used to insert the implant being held by the implant holder 125 into a patient.
  • the handle member 115 can include an elongated proximal portion 510 that can be grasped by a user and the distal attachment portion 130 that can releaseably attached to the implant 110 via the implant holder 125 .
  • the proximal portion 510 of the handle member 115 can be sized and shaped to be grasped by a user and can have an ergonomic shape that facilitates quick and easy positioning of the implant 110 and release of the implant 110 into the patient.
  • the distal attachment portion 130 of the handle member 115 can be inserted into the central channel 103 of the carrier member 105 after removal of the guide sleeve 120 from the central channel 103 .
  • the attachment portion 130 can removably attach, engage or otherwise mate with the implant holder 125 of the carrier member 105 , which holds the implant 110 (see FIG. 11 ).
  • the handle member 115 can be removed from the carrier member 105 such that it takes the implant holder 125 (and attached implant 110 ) out of the carrier member 105 along with it.
  • the handle member 115 can then be used to manipulate the implant 110 held by the implant holder 125 such that the implant 110 can be inserted into an eye.
  • FIG. 12 shows handle member 115 after it has been removed from the carrier member 105 with the removable implant holder 125 now attached to the handle member 115 .
  • the proximal end 902 of the implant holder 125 can be reversibly coupled to a region of the shell 101 by a locking mechanism configured to unlock the implant holder 125 from the shell 101 and lock the implant holder 125 onto the handle member 115 once the handle member 115 is inserted into the carrier member 105 .
  • the locking mechanism can include the indentation 912 located near a proximal end 910 of each grasper 905 and the tab 914 adjacent the indentation 912 having the projection 918 on its inner surface.
  • the projection 918 can have a ramped proximal end and a flat lower surface 920 .
  • the correspondingly-shaped element 410 of the shell 101 can rest within the indentation 912 .
  • the attachment portion 130 of the handle 115 is inserted through the implant holder 125
  • the projection 918 on the inner surface of the tab 914 can insert within the recess 505 near the distal end of the attachment portion 130 .
  • Distal movement of the attachment portion 130 along arrow D through the interior 901 of the implant holder 125 can cause the tab 914 to flex slightly outward as the outer surface of the distal end of the attachment portion 130 slides past the ramped surface of the projection 918 on the inner surface of the tab 914 .
  • the tab 914 can flex back inward such that the projection 918 snaps into the recess 505 .
  • the recess 505 and the projection 918 can have corresponding shapes such that the projection 918 can be received at least in part within the recess 505 .
  • Further distal movement of the handle 115 through the interior 901 of the implant holder 125 can be prevented due to contact between the distal-most end of the attachment portion 130 and a surface 925 of the interior 901 of the implant holder 125 .
  • a region of the attachment portion 130 between the recess 505 and the distal-most end of the attachment portion 130 can be captured between the projection 918 and this surface 925 (see FIG. 13 ).
  • Proximal withdrawal of the handle 115 along arrow P from the central channel 103 of the shell 101 can cause a lower surface 920 of the projection 918 to abut a distal wall 515 of the recess 505 causing the implant holder 125 to be withdrawn with the handle 115 in a proximal direction along arrow P out from the central channel 103 .
  • the handle member 115 can have at least one deployment mechanism including an actuator 705 , such as a button, knob, slider, etc., that can be actuated to detach the implant 110 from the implant holder 125 and handle member 115 .
  • the actuation of the actuator 705 can simply release the implant 110 or it can push or otherwise expel the implant 110 from the handle member 115 .
  • FIGS. 14A and 14B shows an implementation of a deployment mechanism that releases the implant 110 from the handle member 115 upon actuation of the actuator 705 .
  • the implant holder 125 can include a pair of movable tips or graspers 905 that grasp the implant 110 such that when the handle member 115 is inserted within the interior 901 of the implant holder 125 the graspers 905 secure the implant 110 to the handle member 115 .
  • the graspers 905 can be positioned such that they hold the implant 110 in a secured position relative to the handle member 115 .
  • the actuator 705 is depressed, the graspers 905 can separate and release the implant 110 as shown in FIG. 14B .
  • FIG. 15A-15B show cross-sectional views of an implementation of the deployment mechanism.
  • the actuator 705 can be pressed (or slide) so as to exert a force onto a spring held slider member 1005 .
  • the force of the actuator 705 can slide the slide member 1005 to a position that causes the graspers 905 to open.
  • the amount of force required to slide the slider member 1005 forward and open the graspers 905 can be variable.
  • the slider member 1005 and the actuator interface at ramped connection can have different ramp angles resulting in a smoothing of the force required for the user to open the handle tips.
  • the actuator 705 can include an actuator element 701 configured to pivot around a pivot pin 710 when the actuator 705 is depressed towards an upper surface 520 of the handle member 115 .
  • the actuator element 701 can also include a projection 715 extending from its lower surface 720 such that as the element 701 pivots around the pivot pin 710 the projection 715 is moved downwards such that the ramped surface 725 of the projection 715 slides along a ramped surface 1010 of the slider member 1005 . This contact between the ramped surface 725 of the projection 715 against the ramped surface 1010 of the slider member 1005 can cause the slider member 1005 to move in a proximal direction against the force of the spring 730 compressing the spring 730 .
  • the slider member 1005 can have a forked region 1015 near its distal end.
  • the attachment portion 130 of the handle member 115 can interface with the forked region 1015 .
  • the attachment portion 130 can include a first arm 525 rotatably coupled to a second arm 530 around a pivot point 535 .
  • the first arm 525 and second arm 530 can be biased such as by a spring or other element such that their distal ends 540 are urged towards one another.
  • the distal region 540 of the arms 525 , 530 can extend within the interior 901 of the implant holder 125 such that the projections 918 of the implant holder 125 mate with the recesses 505 on the arms 525 , 530 .
  • a region 545 of the arms 525 , 530 proximal of the pivot point 535 can interface with the forked region 1015 of the slider member 1005 .
  • a first prong 1020 a of the forked region 1015 can rest against a first region 550 of the arm 525 and a second prong 1020 b of the forked region 1015 can rest against a second region 550 of the arm 530 (see FIG. 14A ).
  • the first and second prongs 1020 a , 1020 b can slide relative to the arms 525 , 530 such that they abut a ramped proximal end 545 of each respective arm 525 , 530 and cause the arms 525 , 530 to open or pivot relative to one another around pivot point 535 .
  • the distal region 540 of the arms 525 , 530 can move away from one another in a scissor-like movement.
  • the actuator element 701 can be arranged relative to the arms 525 , 530 of the handle member 115 such that as the actuator element 701 is pressed downwards towards the upper surface of the handle member 115 , the arms 525 , 530 can each move outward at an angle away from the longitudinal axis A of the system 100 and from one another.
  • the arms 525 , 530 can be configured to move away from one another such that one arm moves to a first side and the opposing arm moves to a second opposite side away from the longitudinal axis A of the system 100 .
  • the arms 525 , 530 also can be configured to move away from one another such that one arm moves upwards and one arm moves downwards away from the longitudinal axis A of the system 100 .
  • the actuator element 701 can be positioned on an upper surface of the handle member 115 from the point of view of the user such that the actuator element 701 is pressed using a thumb and the actuator element 701 moved towards the upper surface of the handle member 115 .
  • the actuator element 701 also can be positioned on a lower surface of the handle member 115 from the point of view of the user such that the actuator element 701 is pressed using a finger and the actuator element 701 moved towards the lower surface of the handle member 115 .
  • the kit can include sterile packaging within which one or more components of the system 100 can be contained including the carrier member 105 having a guide sleeve 120 and implant holder 125 attached.
  • An implant 110 can be held within the implant holder 125 or the implant 110 can be contained within sterile packaging separated from the system 100 such that the implant 110 is engaged with the implant holder 125 after the sterile kit has been opened.
  • the kit can further include a handle member 115 .
  • the kit can further include needle assembly 210 configured to couple to a pre-filled syringe. Alternatively, the kit can include the syringe.
  • the kit can further include a removal tool.
  • the kit can include a carrier member 105 having a guide sleeve 120 and having an implant holder 125 coupled to the shell 101 of the carrier member 105 .
  • the implant holder 125 can be reversibly coupled to an implant 110 .
  • the implant 110 can be empty.
  • the kit can further include a handle member 115 configured to engage with the implant holder 125 holding the implant 110 after the implant 110 has been filed with a drug.
  • a syringe 205 can be provided that is configured to interdigitate with a portion of a carrier member 105 such that a needle of the syringe 205 can insert through a proximal portion of the implant 110 being held by the carrier member 105 to fill the implant 110 with a drug.
  • the syringe 205 can be pre-filled with one or more therapeutic agents.
  • the carrier member 105 can include a guide sleeve 120 configured to lock onto a portion of the syringe 205 upon insertion of the syringe 205 into the guide sleeve 120 of the carrier member 105 .
  • the implant 110 can be held by an implant holder 125 locked onto the carrier member 105 , such as within the central channel 103 .
  • the implant holder 125 holding the implant 110 can attach to a portion of a handle member 115 after removal of the syringe 205 from the carrier member 105 upon filling of the implant 110 .
  • the handle member 115 having the implant holder 125 now attached to it can be used to deliver the implant 110 held within the implant holder 125 into a target location of the patient.
  • the kit can include a carrier member 105 having a shell 101 and a guide sleeve 120 , and an implant holder 125 holding an implant 110 .
  • the carrier member 105 can have a central channel 103 that facilitates access to the implant 110 being held by the implant holder 125 , such as for filling with a syringe 205 .
  • the syringe 205 can be part of the kit or a separate component.
  • the syringe 205 can be pre-filled with one or more therapeutic agents or can be empty.
  • the handle member 115 can also be part of the kit or a separate component.
  • the implant 110 can be part of the kit or a separate component. In an interrelated aspect, all of the components can be provided as a single kit or can be provided as separate components.
  • phrases such as “at least one of” or “one or more of” may occur followed by a conjunctive list of elements or features.
  • the term “and/or” may also occur in a list of two or more elements or features. Unless otherwise implicitly or explicitly contradicted by the context in which it is used, such a phrase is intended to mean any of the listed elements or features individually or any of the recited elements or features in combination with any of the other recited elements or features.
  • the phrases “at least one of A and B;” “one or more of A and B;” and “A and/or B” are each intended to mean “A alone, B alone, or A and B together.”
  • a similar interpretation is also intended for lists including three or more items.
  • phrases “at least one of A, B, and C;” “one or more of A, B, and C;” and “A, B, and/or C” are each intended to mean “A alone, B alone, C alone, A and B together, A and C together, B and C together, or A and B and C together.”
US15/325,995 2014-07-15 2015-07-15 Ocular implant delivery device and method Active 2035-11-02 US10258503B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/325,995 US10258503B2 (en) 2014-07-15 2015-07-15 Ocular implant delivery device and method

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462024682P 2014-07-15 2014-07-15
PCT/US2015/040633 WO2016011191A1 (fr) 2014-07-15 2015-07-15 Dispositif et méthode de pose d'implant oculaire
US15/325,995 US10258503B2 (en) 2014-07-15 2015-07-15 Ocular implant delivery device and method

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/040633 A-371-Of-International WO2016011191A1 (fr) 2014-07-15 2015-07-15 Dispositif et méthode de pose d'implant oculaire

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/380,786 Continuation US11337853B2 (en) 2014-07-15 2019-04-10 Ocular implant delivery device and method

Publications (2)

Publication Number Publication Date
US20170165108A1 US20170165108A1 (en) 2017-06-15
US10258503B2 true US10258503B2 (en) 2019-04-16

Family

ID=55079028

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/325,995 Active 2035-11-02 US10258503B2 (en) 2014-07-15 2015-07-15 Ocular implant delivery device and method
US16/380,786 Active 2036-05-25 US11337853B2 (en) 2014-07-15 2019-04-10 Ocular implant delivery device and method
US17/745,007 Pending US20220378609A1 (en) 2014-07-15 2022-05-16 Ocular implant delivery device and method

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/380,786 Active 2036-05-25 US11337853B2 (en) 2014-07-15 2019-04-10 Ocular implant delivery device and method
US17/745,007 Pending US20220378609A1 (en) 2014-07-15 2022-05-16 Ocular implant delivery device and method

Country Status (15)

Country Link
US (3) US10258503B2 (fr)
EP (2) EP3169289B1 (fr)
JP (1) JP6581194B2 (fr)
KR (1) KR102416726B1 (fr)
CN (1) CN106687079B (fr)
AU (1) AU2015289625B2 (fr)
BR (1) BR112017000774B1 (fr)
CA (1) CA2955186C (fr)
ES (1) ES2803102T3 (fr)
IL (1) IL250079B (fr)
MX (1) MX2017000609A (fr)
MY (1) MY182497A (fr)
RU (1) RU2695563C2 (fr)
WO (1) WO2016011191A1 (fr)
ZA (1) ZA201700387B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022098825A1 (fr) 2020-11-04 2022-05-12 Aerie Pharmaceuticals, Inc. Implant intraoculaire pour administration de médicament

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3045436A1 (fr) 2009-01-29 2010-08-05 Forsight Vision4, Inc. Administration d'un medicament dans le segment posterieur
WO2013116061A1 (fr) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Procédés et instrument pour l'insertion et le retrait de dispositifs thérapeutiques
CA2907681C (fr) 2013-03-28 2022-11-22 Forsight Vision4, Inc. Implant ophtalmique pour administrer des substances therapeutiques
RU2695563C2 (ru) 2014-07-15 2019-07-24 Форсайт Вижн4, Инк. Способ и устройство для доставки глазного имплантата
EP3179968B1 (fr) 2014-07-24 2019-09-11 Sinopsys Surgical, Inc. Dispositifs d'implant d'accès aux sinus paranasaux et produits et procédés associés
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CN114587774A (zh) 2014-11-10 2022-06-07 弗赛特影像4股份有限公司 治疗眼睛的系统
KR20180084104A (ko) 2015-11-20 2018-07-24 포사이트 비젼4, 인크. 연장 방출 약물 전달 장치를 위한 다공성 구조물
AR108177A1 (es) 2016-04-05 2018-07-25 Forsight Vision4 Inc Dispositivos de suministro de fármacos oculares implantables
JP7408542B2 (ja) 2017-09-20 2024-01-05 シノプシス サージカル インコーポレイテッド 副鼻腔流体アクセス埋め込み器具、アセンブリ、キット、および方法
BR112020010053A2 (pt) 2017-11-21 2020-11-03 Forsight Vision4, Inc. aparelho para troca de fluido para sistema de liberação de porta expansível e métodos de uso do mesmo
CN110507476B (zh) * 2019-09-12 2021-10-26 格劳科斯公司 制造眼部植入物输送装置的方法
US20230101775A1 (en) * 2020-02-27 2023-03-30 Istar Medical Package for Retaining and Dispensing a Delivery Shaft Assembly for Delivery of an Implant
US20220054311A1 (en) * 2020-08-12 2022-02-24 United States Government As Represented By The Department Of Veterans Affairs Eye Drop Dispensing Apparatus
WO2023044093A1 (fr) 2021-09-20 2023-03-23 Mott Corporation Revêtement polymère pour dispositifs médicaux et procédé de fabrication
CN114848289A (zh) * 2022-05-06 2022-08-05 海思盖德(苏州)生物医学科技有限公司 一种眼部植入物输送器
CN114983670A (zh) * 2022-05-30 2022-09-02 海思盖德(苏州)生物医学科技有限公司 一种眼内植入物输送器

Citations (346)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2564977A (en) 1949-01-19 1951-08-21 Hu Quang Hsi Medical injecting apparatus
US2585815A (en) 1947-01-16 1952-02-12 Mclintock Duncan Menzies Injection syringe
US3232117A (en) 1962-09-14 1966-02-01 Roger Gilmont Instr Inc Micrometer buret
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3618604A (en) 1969-06-09 1971-11-09 Alza Corp Ocular insert
US3641237A (en) 1970-09-30 1972-02-08 Nat Patent Dev Corp Zero order release constant elution rate drug dosage
US3828777A (en) 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US3902495A (en) 1974-01-28 1975-09-02 Cavitron Corp Flow control system
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3949748A (en) 1974-09-26 1976-04-13 Oscar Malmin Injection syringe having aspirating and metering capabilities
US3949750A (en) 1974-10-07 1976-04-13 Freeman Jerre M Punctum plug and method for treating keratoconjunctivitis sicca (dry eye) and other ophthalmic aliments using same
US3961628A (en) 1974-04-10 1976-06-08 Alza Corporation Ocular drug dispensing system
US3977404A (en) 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US3995635A (en) 1971-09-09 1976-12-07 Alza Corporation Ocular insert
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4014334A (en) 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4014333A (en) 1975-09-22 1977-03-29 Mcintyre David J Instrument for aspirating and irrigating during ophthalmic surgery
US4034756A (en) 1971-01-13 1977-07-12 Alza Corporation Osmotically driven fluid dispenser
US4034758A (en) 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4111201A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4135514A (en) 1974-12-23 1979-01-23 Alza Corporation Osmotic releasing system for administering ophthalmic drug to eye of animal
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4220153A (en) 1978-05-08 1980-09-02 Pfizer Inc. Controlled release delivery system
US4220152A (en) 1978-05-08 1980-09-02 Pfizer Inc. Delivery system
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4298000A (en) 1978-11-08 1981-11-03 Minnesota Mining And Manufacturing Company Fluid dispensing device
US4300557A (en) 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4309776A (en) 1980-05-13 1982-01-12 Ramon Berguer Intravascular implantation device and method of using the same
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4475916A (en) 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
US4484922A (en) 1981-06-25 1984-11-27 Rosenwald Peter L Occular device
US4519801A (en) 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4609374A (en) 1985-04-22 1986-09-02 Alza Corporation Osmotic device comprising means for governing initial time of agent release therefrom
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4673405A (en) 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4693886A (en) 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
US4712550A (en) 1985-04-08 1987-12-15 Sinnett Kevin B Retinal tack
US4737150A (en) 1985-05-10 1988-04-12 Intermedicat Gmbh Two-cannula syringe
WO1988004573A1 (fr) 1986-12-23 1988-06-30 The Liposome Company, Inc. Preparation antibiotique a base de liposomes
US4777049A (en) 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
US4781675A (en) 1985-11-27 1988-11-01 White Thomas C Infusion cannula
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US4865846A (en) 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US4883459A (en) 1983-07-29 1989-11-28 Reynaldo Calderon Retrograde perfusion
WO1990007545A2 (fr) 1988-12-30 1990-07-12 Anderson David M Matieres microporeuses et matieres d'hydrogel stabilisees
EP0228185B1 (fr) 1985-11-27 1990-07-25 Thomas C. White Dispositif implantable dans les tissus humains pour disperser des liquides
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5084021A (en) 1990-11-02 1992-01-28 Baldwin Brian E Patient controlled infusion apparatus and method
US5098443A (en) 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5128145A (en) 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5174999A (en) 1988-12-13 1992-12-29 Alza Corporation Delivery system comprising fluid ingress and drug egress
US5178622A (en) 1991-11-01 1993-01-12 Lehner Ii Robert H Instrument for implanting a soft intraocular lens
US5277912A (en) 1991-04-05 1994-01-11 Eli Lilly And Company Sustained release capsule and formulations
US5282829A (en) 1991-08-15 1994-02-01 United States Surgical Corporation Hollow body implants
US5300114A (en) 1992-05-04 1994-04-05 Allergan, Inc. Subconjunctival implants for ocular drug delivery
US5322691A (en) 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US5334189A (en) 1991-06-03 1994-08-02 Wade Stephen E Device for controlled diffusion of a chemical substance
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5413572A (en) 1990-04-02 1995-05-09 Alza Corporation Osmotic dosage system for liquid drug delivery
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
EP0671165A2 (fr) 1994-02-09 1995-09-13 Collagen Corporation Système injectable pour la délivrance d'un médicament à base de collagène et son utilisation
WO1995028984A1 (fr) 1994-04-25 1995-11-02 Escalon Ophthalmics, Inc. Pointe pour l'administration intraoculaire de medicaments et procede permettant d'introduire et d'enlever ladite pointe
US5516522A (en) 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5554132A (en) 1995-03-30 1996-09-10 Abbott Laboratories Hand grip for use with syringe
WO1997029850A1 (fr) 1996-02-15 1997-08-21 Nomix-Chipman Limited Pistolet pulverisateur
US5681572A (en) 1991-10-18 1997-10-28 Seare, Jr.; William J. Porous material product and process
US5702414A (en) 1995-05-14 1997-12-30 Optonol Ltd Method of implanting an intraocular implant
WO1998025982A1 (fr) 1996-12-13 1998-06-18 Novartis Ag Polymeres de polyorganosiloxane poreux
US5770076A (en) 1994-03-07 1998-06-23 The Regents Of The University Of California Micromachined capsules having porous membranes and bulk supports
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5830546A (en) 1991-10-03 1998-11-03 Holvis Holzstoff S.A. Reservoir system for prolonged diffusion of an active principle
US5830173A (en) 1994-12-12 1998-11-03 Avery; Robert Logan Intravitreal medicine delivery
US5836935A (en) 1994-11-10 1998-11-17 Ashton; Paul Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5868697A (en) 1995-05-14 1999-02-09 Optonol Ltd. Intraocular implant
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US5916584A (en) 1994-10-25 1999-06-29 Daratech Proprietary Limited Controlled release container with core and outer shell
US5928662A (en) 1996-07-31 1999-07-27 Phillips; Andrew F. Ocular drug delivery device
US5951512A (en) 1996-05-28 1999-09-14 Horizon Medical Products, Inc. Infusion port with modified drug reservoir
US5972369A (en) 1997-03-31 1999-10-26 Alza Corporation Diffusional implantable delivery system
US5985328A (en) 1994-03-07 1999-11-16 Regents Of The University Of California Micromachined porous membranes with bulk support
US6039712A (en) 1997-11-04 2000-03-21 Terence M. Fogarty Implantable injection port
US6096070A (en) 1995-06-07 2000-08-01 Med Institute Inc. Coated implantable medical device
WO2000048660A1 (fr) 1999-02-18 2000-08-24 Alcove Surfaces Gmbh Implant
US6196993B1 (en) 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
WO2001026714A1 (fr) 1999-10-12 2001-04-19 Durect Corporation Regulation de la distribution d'un medicament par deviation de son trajet d'ecoulement
WO2001050943A2 (fr) 2000-01-12 2001-07-19 Becton, Dickinson And Company Systemes et procedes permettant de reduire la pression intraoculaire
US6303290B1 (en) 2000-09-13 2001-10-16 The Trustees Of The University Of Pennsylvania Encapsulation of biomaterials in porous glass-like matrices prepared via an aqueous colloidal sol-gel process
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US20020026176A1 (en) 2000-08-30 2002-02-28 Varner Signe Erickson Devices for intraocular drug delivery
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6413540B1 (en) 1999-10-21 2002-07-02 Alcon Universal Ltd. Drug delivery device
US20020086051A1 (en) 2001-01-03 2002-07-04 Santos Viscasillas Sustained release drug delivery devices with coated drug cores
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US6420399B1 (en) 1999-06-18 2002-07-16 Alcon Manufacturing, Ltd. Topical ophthalmic mast cell stabilizers for treating allergic eye disease
US20020106395A1 (en) 2001-01-03 2002-08-08 Brubaker Michael J. Sustained release drug delivery devices with prefabricated permeable plugs
US20020110635A1 (en) 2001-01-26 2002-08-15 Brubaker Michael J. Process for the production of sustained release drug delivery devices
US20020110591A1 (en) 2000-12-29 2002-08-15 Brubaker Michael J. Sustained release drug delivery devices
US20020110592A1 (en) 2001-01-03 2002-08-15 Brubaker Michael J. Sustained release drug delivery devices with multiple agents
US20020116009A1 (en) * 2000-05-08 2002-08-22 Fraser Robert D. Medical installation tool
US6472162B1 (en) 1999-06-04 2002-10-29 Thermogenesis Corp. Method for preparing thrombin for use in a biological glue
US20030005945A1 (en) 2000-03-13 2003-01-09 Hiroyuki Onishi Method for surface-treatment, surface-treated article and device for surface treatment
US20030014036A1 (en) 2001-06-12 2003-01-16 Varner Signe Erickson Reservoir device for intraocular drug delivery
US20030118649A1 (en) 2001-10-04 2003-06-26 Jinming Gao Drug delivery devices and methods
US20030119177A1 (en) 2001-11-15 2003-06-26 Lewis Gruber Sample chip
US6605066B1 (en) 1998-09-18 2003-08-12 Imedex Biomateriaux Device for forming and delivering a mixture
US20030176854A1 (en) 2002-03-11 2003-09-18 Alcon, Inc. Implantable drug delivery system
US20030185872A1 (en) 2002-03-27 2003-10-02 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US20030212383A1 (en) 2001-01-05 2003-11-13 Dana Cote System and methods for reducing intraocular pressure
US20030235603A1 (en) 2002-06-19 2003-12-25 Schwarz Marlene C. Multiphase polymeric drug release region
US20040011651A1 (en) 1996-01-31 2004-01-22 Board Of Regents, The University Of Texas System Method and apparatus for fractionation using conventional dielectrophoresis and field flow fractionation
US20040019325A1 (en) 2002-07-29 2004-01-29 Medrip Ltd. Syringe Pump
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US20040092911A1 (en) 2001-07-23 2004-05-13 Yoseph Yaacobi Ophthalmic drug delivery device
US20040106906A1 (en) 2001-07-23 2004-06-03 Yoseph Yaacobi Opthalmic drug delivery device
US20040209359A1 (en) 2001-07-19 2004-10-21 Avner Yayon Plasma protein matrices and methods for their preparation
US20040230183A1 (en) 2003-02-18 2004-11-18 Wisam Breegi Drug delivery device and syringe for filling the same
US20040238392A1 (en) 2003-06-02 2004-12-02 Peterson Rod T. Intraocular lens and cartridge packaging with lens-loading function
US20040260380A1 (en) 2003-06-18 2004-12-23 D-Crown Ltd Devices for delivering multiple stenting structures in situ
US20040260381A1 (en) 2003-06-18 2004-12-23 D-Crown Ltd Devices and methods for forming stenting structures in situ
WO2004112653A2 (fr) 2003-06-18 2004-12-29 D-Crown Ltd. Dispositifs et procedes pour l'apport et la formation in situ de structures d'endoprotheses individuelles et multiples
WO2005016401A2 (fr) 2003-06-13 2005-02-24 Becton Dickinson And Company Administration intradermique amelioree d'agents bioactifs
US20050055031A1 (en) * 2003-09-10 2005-03-10 Roy Lim Devices and methods for inserting spinal implants
US20050064010A1 (en) 2003-09-18 2005-03-24 Cooper Eugene R. Transscleral delivery
WO2005028006A1 (fr) 2003-09-24 2005-03-31 Medi-Stream Pty Ltd Support pour medicament
US20050074497A1 (en) 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050112759A1 (en) 2003-06-20 2005-05-26 Milica Radisic Application of electrical stimulation for functional tissue engineering in vitro and in vivo
US20050113806A1 (en) 2001-08-29 2005-05-26 De Carvalho Ricardo A.P. Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues
US20050119737A1 (en) 2000-01-12 2005-06-02 Bene Eric A. Ocular implant and methods for making and using same
US20050143363A1 (en) 2002-09-29 2005-06-30 Innorx, Inc. Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid of the retina; and related methods for treatment and/or prevention of retinal diseases
US20050154399A1 (en) 2002-09-18 2005-07-14 Allergan, Inc. Apparatus for delivery of ocular implants
US20050181018A1 (en) 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
WO2005091922A2 (fr) 2004-03-03 2005-10-06 Becton, Dickinson And Company Procedes et dispositifs pour l'amelioration de l'administration cutanee d'une substance
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20050244467A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended release biodegradable ocular implants
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
WO2005110436A2 (fr) 2004-04-30 2005-11-24 Allergan, Inc. Implants a liberation prolongee contenant des macromolecules et leurs procedes
US20050271706A1 (en) 2003-05-02 2005-12-08 Anderson Aron B Controlled release bioactive agent delivery device
US20050277802A1 (en) 2004-02-12 2005-12-15 Larsen Charles E Method and apparatus for intraocular brachytherapy
US6976982B2 (en) 2001-01-09 2005-12-20 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
WO2006015385A2 (fr) 2004-08-06 2006-02-09 Sopherion Therapeutics, Inc. Peptides anti-angiogènes et leurs procédés d'utilisation
WO2006014484A2 (fr) 2004-07-02 2006-02-09 Surmodics, Inc. Procedes et dispositifs pour le traitement d'affections oculaires
US20060039952A1 (en) 2003-07-10 2006-02-23 Yoseph Yaacobi Ophthalmic drug delivery device
WO2006023530A2 (fr) 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions et procedes permettant d'ameliorer le systeme structurel et fonctionnel de la reorganisation et de la recuperation du systeme nerveux
US20060052754A1 (en) 2004-09-04 2006-03-09 Fields Douglas W Thumb trigger syringe pole
US20060057277A1 (en) 2004-09-10 2006-03-16 Chappa Ralph A Methods, devices, and coatings for controlled active agent release
WO2006031388A2 (fr) 2004-08-20 2006-03-23 Hyperbranch Medical Technology, Inc. Polymeres dendritiques et gels reticules: utilisations dans des applications orthopediques
WO2006031358A2 (fr) 2004-08-13 2006-03-23 Hyperbranch Medical Technology, Inc. Polymeres dendritiques, gels reticules, et leurs utilisations comme agents de scellement et lentilles ophtalmiques
US20060073182A1 (en) 2004-10-01 2006-04-06 Wong Vernon G Conveniently implantable sustained release drug compositions
US7026329B2 (en) 1992-09-21 2006-04-11 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
WO2006044614A2 (fr) 2004-10-14 2006-04-27 Sopherion Therapeutics, Inc. Peptides anti-angiogeniques et procedes d'utilisation de ceux-ci
US20060129215A1 (en) 2004-12-09 2006-06-15 Helmus Michael N Medical devices having nanostructured regions for controlled tissue biocompatibility and drug delivery
EP1671624A1 (fr) 2003-05-02 2006-06-21 SurModics, Inc. Un système bioactive pour la libération controlée d'un agent bioactif dans la section postérieure oculaire
US20060154981A1 (en) 2005-01-12 2006-07-13 Alcon, Inc. Method of reducing intraocular pressure and treating glaucoma
US7077848B1 (en) 2000-03-11 2006-07-18 John Hopkins University Sutureless occular surgical methods and instruments for use in such methods
WO2006082588A2 (fr) 2005-02-07 2006-08-10 Pharmalight Inc. Procede et dispositif d'administration ophtalmique d'ingredients pharmaceutiquement actifs
US7090681B2 (en) 2002-09-18 2006-08-15 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20060200097A1 (en) 2003-01-24 2006-09-07 Doheny Retina Institute Reservoirs with subretinal cannula for subretinal drug delivery
US7117870B2 (en) 2004-07-26 2006-10-10 Clarity Corporation Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
WO2006108054A2 (fr) 2005-04-05 2006-10-12 The Ohio State University Systeme de distribution par diffusion et procedes de fabrication
US20060233858A1 (en) 2005-03-08 2006-10-19 Allergan, Inc. Systems and methods providing targeted intraocular drug delivery
US20060246112A1 (en) 2002-01-18 2006-11-02 Snyder Michael E Sustained release ophthalmological device and method of making and using the same
US20060258000A1 (en) 2003-02-26 2006-11-16 Allen Jared W Use of steady-state oxygen gradients to modulate animal cell functions
US20060258994A1 (en) 2005-05-12 2006-11-16 Avery Robert L Implantable delivery device for administering pharmacological agents to an internal portion of a body
US20060257450A1 (en) 2005-03-21 2006-11-16 Sreenivasu Mudumba Drug delivery systems for treatment of diseases or conditions
WO2006125106A1 (fr) 2005-05-18 2006-11-23 Surmodics, Inc. Instrument d'insertion destine aux dispositifs medicaux non lineaires
US7141152B2 (en) 2000-03-16 2006-11-28 Le Febre David A Analyte species separation system
WO2006127962A2 (fr) 2005-05-25 2006-11-30 Becton, Dickinson And Comapny Formulations particulaires pour une administration intradermique d'agents biologiquement actifs
US20060276738A1 (en) 2005-06-06 2006-12-07 Becker Bruce B Lacrimal drainage bypass device and method
WO2006138609A2 (fr) 2005-06-17 2006-12-28 Dynamis Therapeutics, Inc. Traitement d'etats inflammatoires
US20070020336A1 (en) 2005-07-22 2007-01-25 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20070026037A1 (en) 2005-07-29 2007-02-01 Kloke Timothy M Devices, articles, coatings, and methods for controlled active agent release or hemocompatibility
US7181287B2 (en) 2001-02-13 2007-02-20 Second Sight Medical Products, Inc. Implantable drug delivery device
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US7195774B2 (en) 2001-08-29 2007-03-27 Carvalho Ricardo Azevedo Ponte Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues
US7195778B2 (en) 2001-07-10 2007-03-27 Teva Pharmaceutical Industries Ltd. Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US20070071756A1 (en) 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an agent to ameliorate inflammation
US20070072933A1 (en) 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an ocular agent
WO2007035621A1 (fr) 2005-09-16 2007-03-29 (Osi) Eyetech, Inc. Seringue oculaire
WO2007038453A2 (fr) 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Administration d'un agent pour l'amelioration de l'inflammation
US20070077270A1 (en) 2005-03-28 2007-04-05 Clemson University Delivery devices and methods for long-term, targeted delivery of therapeutic agents to the eye and ear
WO2007044534A2 (fr) 2005-10-06 2007-04-19 Trophogen, Inc. Analogues du vegf et procedes d'utilisation
WO2007047744A2 (fr) 2005-10-14 2007-04-26 Alcon, Inc. Methode de traitement de la forme primaire et de la forme secondaire du glaucome
US7211272B2 (en) 2003-12-22 2007-05-01 Bausch & Lomb Incorporated Drug delivery device
US20070128644A1 (en) 2005-12-01 2007-06-07 Canon Kabushiki Kaisha Fluid control method and fluid control apparatus
WO2007066339A1 (fr) 2005-12-07 2007-06-14 Ramot At Tel Aviv University Ltd. Structures composites pour l’administration de médicaments
US20070131611A1 (en) 2005-12-13 2007-06-14 General Electric Company Membrane-based article and associated method
US20070131610A1 (en) 2005-12-13 2007-06-14 General Electric Company Membrane-based apparatus and associated method
US20070141111A1 (en) 2003-08-20 2007-06-21 Bioretec Oy Porous medical device and method for its manufacture
WO2007084582A2 (fr) 2006-01-17 2007-07-26 Forsight Labs, Llc Dispositif de traitement d’administration de medicament
WO2007084765A2 (fr) 2006-01-19 2007-07-26 Potentia Pharmaceuticals, Inc. Traitement combinatoire injectable destine a des troubles ophtalmiques
US20070191863A1 (en) 2006-01-17 2007-08-16 De Juan Eugene Jr Glaucoma Treatment Device
US20070203174A1 (en) 2006-02-27 2007-08-30 Alcon Manufacturing, Ltd. Method of treating glaucoma
US20070212397A1 (en) 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
US7276050B2 (en) 2004-03-02 2007-10-02 Alan Franklin Trans-scleral drug delivery method and apparatus
US20070235331A1 (en) 2003-07-25 2007-10-11 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US20070243230A1 (en) 2006-03-31 2007-10-18 Forsight Labs, Llc Nasolacrimal Drainage System Implants for Drug Therapy
WO2007117394A2 (fr) 2006-03-31 2007-10-18 Dynamis Therapeutics, Inc. Compositions et procedes relatifs aux inhibiteurs de la fructosamine-3-kinase
US20070260201A1 (en) 2006-05-02 2007-11-08 Georgia Tech Research Corporation Method for drug delivery to ocular tissue using microneedle
EP1337284B1 (fr) 2000-09-06 2007-12-05 Alcon Inc. Compositions de revetement a pouvoir adhesif variable pour implants ophtalmiques
US20080004329A1 (en) 2006-06-29 2008-01-03 Jazz Pharmaceuticals Pharmaceutical compositions of ropinirole and methods of use thereof
WO2008003043A2 (fr) 2006-06-28 2008-01-03 Surmodics, Inc. Matrice dégradable et matrice non dégradable en association pour la libération d'un agent actif
US20080003219A1 (en) 2005-09-26 2008-01-03 Minu, L.L.C. Delivery of an ocular agent
WO2008011125A2 (fr) 2006-07-20 2008-01-24 Neurosystec Corporation Dispositifs, systèmes et procédés destinés à administrer des médicaments ophtalmiques
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US20080057561A1 (en) 2006-08-29 2008-03-06 Canon Kabushiki Kaisha Cell culture treatment apparatus and cell culture treatment method
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US20080069854A1 (en) 2006-08-02 2008-03-20 Inframat Corporation Medical devices and methods of making and using
WO2008033924A2 (fr) 2006-09-12 2008-03-20 Board Of Regents Of The University Of Nebraska Méthodes et compositions pour l'administration ciblée d'agents thérapeutiques
WO2008040062A1 (fr) 2006-10-05 2008-04-10 Medi-Stream Pty Ltd Dispositif pour médicament
WO2008045272A2 (fr) 2006-10-06 2008-04-17 Dynamis Therapeutics, Inc. Compositions et procédés éclaircissante pour la peau
US20080089923A1 (en) 2006-09-29 2008-04-17 Burkstrand Michael J Biodegradable ocular implants and methods for treating ocular conditions
US20080097459A1 (en) 2004-04-22 2008-04-24 Advanced Vision Science, Inc. Device For The Insertion Of Deformable Intra-Ocular Lenses
WO2008052145A2 (fr) 2006-10-25 2008-05-02 Revalesio Corporation Procédés de traitement thérapeutique des yeux et d'autres tissus humains à l'aide d'une solution enrichie en oxygène
US20080111282A1 (en) 2006-11-10 2008-05-15 Baojun Xie Process for Making Three Dimensional Objects From Dispersions of Polymer Colloidal Particles
WO2008061043A2 (fr) 2006-11-10 2008-05-22 Glaukos Corporation Dérivation uvéosclérale et procédés pour son implantation
US20080124372A1 (en) 2006-06-06 2008-05-29 Hossainy Syed F A Morphology profiles for control of agent release rates from polymer matrices
US20080145406A1 (en) 2006-12-18 2008-06-19 Alcon Manufacturing Ltd. Devices and methods for ophthalmic drug delivery
US20080147021A1 (en) 2006-12-15 2008-06-19 Jani Dharmendra M Drug delivery devices
US20080154241A1 (en) 2006-12-07 2008-06-26 Burkstrand Michael J Latent stabilization of bioactive agents releasable from implantable medical articles
US20080167600A1 (en) 2005-09-26 2008-07-10 Peyman Gholam A Device for delivery of an agent to the eye and other sites
US20080181930A1 (en) 2007-01-31 2008-07-31 Alcon Research, Ltd. Punctal Plugs and Methods of Delivering Therapeutic Agents
US20080200922A1 (en) 2007-02-16 2008-08-21 Brown David C Apparatus for inserting flexible medical implant
US20080213611A1 (en) 2007-01-19 2008-09-04 Cinvention Ag Porous, non-degradable implant made by powder molding
US20080216736A1 (en) 2006-01-19 2008-09-11 Takeda San Diego, Inc. Microfluidic device with diffusion between adjacent lumens
WO2008116165A2 (fr) 2007-03-21 2008-09-25 Next Safety, Inc. Procédés et systèmes d'administration d'une médication par inhalation
WO2008115290A2 (fr) 2006-10-25 2008-09-25 Revalesio Corporation Méthodes de soins et de traitement de plaies
US20080249501A1 (en) 2007-04-09 2008-10-09 Medtronic Vascular, Inc. Methods for Simultaneous Injection and Aspiration of Fluids During a Medical Procedure
US20080286338A1 (en) 2007-05-15 2008-11-20 Boston Foundation For Sight Drug delivery system with scleral lens
US20080292679A1 (en) 2007-05-24 2008-11-27 Allergan, Inc. Biodegradable drug delivery system
WO2008144919A1 (fr) 2007-05-29 2008-12-04 Angiochem, Inc. Polypeptides de type aprotinine pour administrer à des tissus des agents conjugués à ceux-ci
US20090005864A1 (en) 1996-03-18 2009-01-01 Eggleston Harry C Modular intraocular implant
US7476510B2 (en) 1997-05-29 2009-01-13 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
WO2009012075A1 (fr) 2007-07-16 2009-01-22 Alcon, Inc. Utilisation d'agents abaissant iop pour traiter des formes primaires et secondaires de glaucome
US20090036827A1 (en) 2007-07-31 2009-02-05 Karl Cazzini Juxtascleral Drug Delivery and Ocular Implant System
US20090043253A1 (en) 2005-10-11 2009-02-12 Blake Podaima Smart medical compliance method and system
WO2009023615A1 (fr) 2007-08-10 2009-02-19 Trustees Of Tufts College Compositions de soie tubulaires et procédés d'utilisation de celles-ci
EP1521572B1 (fr) 2002-07-15 2009-03-04 Alcon, Inc. Film bioeroable pour l'administration de medicaments ophtalmiques
US20090082631A1 (en) 2007-09-24 2009-03-26 Cronin Michael D Elliptical retractor
WO2009046164A1 (fr) 2007-10-05 2009-04-09 Tyco Healthcare Group Lp Ancrage d'étanchéité pour une utilisation dans des procédures chirurgicales
US20090099626A1 (en) 2007-09-07 2009-04-16 Qlt Plug Delivery, Inc. - Qpdi Lacrimal implant detection
US20090104243A1 (en) 2007-09-07 2009-04-23 Qlt Plug Delivery, Inc. - Qpdi Drug cores for sustained release of therapeutic agents
US20090105749A1 (en) 2007-09-07 2009-04-23 Qlt Plug Delivery, Inc. - Qpdi Insertion and extraction tools for lacrimal implants
WO2009055824A1 (fr) 2007-10-25 2009-04-30 Revalesio Corporation Compositions et procédés de traitement d'asthme et de troubles pulmonaires
WO2009055620A1 (fr) 2007-10-25 2009-04-30 Revalesio Corporation Compositions bactériostatiques ou bactériocides et procédés
WO2009055729A1 (fr) 2007-10-25 2009-04-30 Revalesio Corporation Compositions et procédés pour traiter une inflammation
WO2009061607A2 (fr) 2007-11-05 2009-05-14 Bausch & Lomb Incorporated Matières non miscibles à l'eau en tant que véhicules pour l'administration d'un médicament
WO2009073192A2 (fr) 2007-12-04 2009-06-11 Landec Corporation Systèmes et procédés pour délivrer des substances
WO2009086112A2 (fr) 2007-12-20 2009-07-09 University Of Southern California Appareil et procédés pour distribuer des agents thérapeutiques
WO2009089409A2 (fr) 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Système d'injection intravitréen à canules coaxiales et son utilisation
WO2009094466A2 (fr) 2008-01-22 2009-07-30 University Of Florida Research Foundation, Inc. Lentilles de contact pour une libération prolongée d'agents bioactifs contenant des atténuateurs de diffusion
US20090214601A1 (en) 2007-09-28 2009-08-27 Chappa Ralph A Porous Drug Delivery Devices and Related Methods
US20090224064A1 (en) 2008-03-10 2009-09-10 Vapore, Inc. Low Energy Vaporization of Liquids: Apparatus and Methods
US20090234449A1 (en) 2007-12-27 2009-09-17 De Juan Jr Eugene Intraocular, accommodating lens and methods of use
WO2009112878A1 (fr) 2008-03-11 2009-09-17 Raouf Rekik Administration de médicament aux segments antérieur et postérieur de l'œil à l'aide de gouttes ophtalmiques
WO2009117112A2 (fr) 2008-03-21 2009-09-24 Novartis Ag Appareil de dispersion de poudre, procédé de fabrication et d’utilisation de l’appareil, composants pouvant être utilisés sur l’appareil et d’autres dispositifs, et divers agents actifs
WO2009124096A1 (fr) 2008-03-31 2009-10-08 Altea Therapeutics Corporation Système d’administration de perméant et procédés d'utilisation de celui-ci
US20090258069A1 (en) 2008-04-15 2009-10-15 John Burnier Delivery of LFA-1 antagonists to the gastrointestinal system
US20090263346A1 (en) 2006-12-05 2009-10-22 David Taft Systems and methods for delivery of drugs
WO2009134929A2 (fr) 2008-05-01 2009-11-05 Revalesio Corporation Compositions et méthodes de traitement de troubles digestifs
US7615141B2 (en) 2003-10-03 2009-11-10 University Of Washington Electrochemical micromanufacturing system and method
WO2009137777A2 (fr) 2008-05-08 2009-11-12 Replenish Pumps, Llc Dispositifs implantables d'administration de médicaments, et appareils et procédés de remplissage de ces dispositifs
US20090280470A1 (en) 2006-02-24 2009-11-12 Rosetta Inpharmatics Llc Extraction and diagnostic fluid devices, systems and methods of use
US20090281621A1 (en) 2008-05-07 2009-11-12 Becker Bruce B Punctal anchor for lacrimal stent, introducer tool and method
US20090326448A1 (en) 2006-04-18 2009-12-31 Pingan Huo Sterile Drug-Mixing Syringe
US20100004189A1 (en) 2007-10-25 2010-01-07 Revalesio Corporation Compositions and methods for treating cystic fibrosis
US20100010452A1 (en) 2007-01-09 2010-01-14 Fovea Pharmaceuticals Apparatus for intra-ocular injection
US20100008997A1 (en) 2007-10-25 2010-01-14 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
US20100009008A1 (en) 2007-10-25 2010-01-14 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
WO2010008424A2 (fr) 2008-04-04 2010-01-21 Novartis Ag Dispositif de production d’aérosols
US20100015157A1 (en) 2004-10-20 2010-01-21 Genentech, Inc. Antibody formulations
US20100016786A1 (en) 2008-07-21 2010-01-21 Arstasis, Inc. Devices, methods, and kits for forming tracts in tissue
US20100011888A1 (en) 2006-07-19 2010-01-21 Janusz Pawliszyn Method and device to extract components contained in a fluid
US20100023033A1 (en) 2008-07-25 2010-01-28 Medtronic Vescular, Inc. Hydrodynamic Thrombectomy Catheter
US20100022943A1 (en) 2008-07-25 2010-01-28 Medtronic Vascular, Inc. Hydrodynamic Thrombectomy Catheter
US20100028442A1 (en) 2006-10-25 2010-02-04 Revalesio Corporation Methods of therapeutic treatment of eyes
US20100028443A1 (en) 2007-10-25 2010-02-04 Revalesio Corporation Compositions and methods for treating inflammation
US20100030136A1 (en) 2006-10-16 2010-02-04 Bruno Dacquay Ophthalmic Injection Device Including Dosage Control Device
US20100034870A1 (en) 2008-04-30 2010-02-11 QLT. Plug Delivery, Inc. Composite lacrimal insert and related methods
WO2010021993A1 (fr) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Procédés d'utilisation de cellules issues du tissu adipeux dans le traitement du système lymphatique et d'une maladie maligne
US7678078B1 (en) 2008-10-21 2010-03-16 KMG Pharma LLC Intravitreal injection device, system and method
US20100100054A1 (en) 2008-10-21 2010-04-22 Michel Cormier Intravitreal injection device and system
US20100100104A1 (en) 2006-06-30 2010-04-22 Aquesys, Inc. Systems for reducing pressure in an organ
US20100114309A1 (en) 2006-12-26 2010-05-06 De Juan Jr Eugene Drug delivery implants for inhibition of optical defects
US20100114017A1 (en) 2002-07-23 2010-05-06 Reverse Medical Corporation Systems and methods for removing obstructive matter from body lumens and treating vascular defects
WO2010062628A1 (fr) 2008-10-27 2010-06-03 Revalesio Corporation Compositions et procédés pour traiter l’asthme et d’autres troubles pulmonaires
WO2010066714A1 (fr) 2008-12-09 2010-06-17 Pari Pharma Gmbh Dispositif d'aérosolthérapie
US20100168535A1 (en) 2006-04-12 2010-07-01 Mark Ries Robinson Methods and apparatuses related to blood analyte measurement system
US20100174272A1 (en) 2009-01-02 2010-07-08 Weiner Alan L In-situ refillable ophthalmic implant
WO2010080987A2 (fr) 2009-01-09 2010-07-15 Becker Bruce B Filière d'intubation lacrymale côte à côte et procédé
US20100185205A1 (en) 2009-01-16 2010-07-22 Allergan, Inc. Interocular injector
WO2010088548A1 (fr) 2009-01-29 2010-08-05 Forsight Labs, Llc Administration d'un médicament dans le segment postérieur
US20100197512A1 (en) 2008-07-11 2010-08-05 Intellicyt Multi-Sample Particle Analyzer and Method for High Throughput Screening
WO2010093945A2 (fr) 2009-02-13 2010-08-19 Glaukos Corporation Implant médicamenteux uvéoscléral et ses procédés d'implantation
WO2010095940A2 (fr) 2009-02-20 2010-08-26 To-Bbb Holding B.V. Sustème d'administration de médicament à base de glutathionne
US20100221309A1 (en) 2001-10-12 2010-09-02 Monosol Rx, Llc Film compositions for delivery of actives
US20100241102A1 (en) 2009-03-23 2010-09-23 Colin Ma Intravitreal injection devices and methods of injecting a substance into the vitreous chamber of the eye
US20100256597A1 (en) 2006-05-02 2010-10-07 Emory University Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle
WO2010126908A1 (fr) 2009-04-27 2010-11-04 Revalesio Corporation Compositions et procédés pour le traitement de la résistance à l'insuline et du diabète
WO2010125416A1 (fr) 2009-04-27 2010-11-04 Raouf Rekik Administration de médicaments dans le segment antérieur et le segment postérieur de l'oeil
US20100286791A1 (en) 2006-11-21 2010-11-11 Goldsmith David S Integrated system for the ballistic and nonballistic infixion and retrieval of implants
WO2010135369A1 (fr) 2009-05-18 2010-11-25 Dose Medical Corporation Implant oculaire à élution de médicament
US20100297120A1 (en) 2007-05-29 2010-11-25 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US20100297193A1 (en) 2006-10-25 2010-11-25 Revalesio Corporation Methods of therapeutic treatment of eyes
US20100303917A1 (en) 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for treating cystic fibrosis
US20100303918A1 (en) 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
WO2010141729A1 (fr) 2009-06-03 2010-12-09 Forsight Labs, Llc Distribution de médicament de segment antérieur
US20100310664A1 (en) 2009-04-27 2010-12-09 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US20100310665A1 (en) 2007-10-25 2010-12-09 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US20100316723A1 (en) 2007-10-25 2010-12-16 Revalesio Corporation Compositions and methods for treating inflammation
US20110009571A1 (en) 2006-12-05 2011-01-13 David Taft Systems and methods for delivery of materials
WO2011008897A2 (fr) 2009-07-14 2011-01-20 Board Of Regents, The University Of Texas System Procédés de réalisation de dispositifs à libération contrôlée avec une cinétique d'ordre zéro
US20110034448A1 (en) 2004-04-30 2011-02-10 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US20110033933A1 (en) 2009-07-15 2011-02-10 Morteza Gharib Method applying hemodynamic forcing and klf2 to initiate the growth and development of cardiac valves
WO2011028850A1 (fr) 2009-09-01 2011-03-10 Northwestern University Distribution d'agents thérapeutiques à l'aide de nanoparticules modifiées par oligonucléotides en tant que véhicules
WO2011034627A2 (fr) 2009-09-21 2011-03-24 Harvard Bioscience, Inc. Procédés et appareils pour introduire des cellules dans un site tissulaire
US7914442B1 (en) 1999-03-01 2011-03-29 Gazdzinski Robert F Endoscopic smart probe and method
US20110081384A1 (en) 2006-10-25 2011-04-07 Revalesio Corporation Methods of wound care and treatment
US20110117083A1 (en) 2009-08-14 2011-05-19 Genentech, Inc. Biological markers for monitoring patient response to vegf antagonists
US20110125178A1 (en) 2009-05-15 2011-05-26 Michael Drews Devices, methods and kits for forming tracts in tissue
CN102098993A (zh) 2008-04-25 2011-06-15 加利福尼亚大学董事会 储藏并注入角膜移植物的装置
WO2011079232A1 (fr) 2009-12-23 2011-06-30 Psivida Us, Inc. Dispositifs d'administration à libération prolongée
US7973068B2 (en) 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US20110196317A1 (en) 2010-02-05 2011-08-11 Victor Lust Implantation instruments, system, and kit for punctal implants
WO2012019136A2 (fr) 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Appareil d'injection et procédé d'administration de médicament
US20120245505A1 (en) 2009-12-16 2012-09-27 Robinson Michael R Intracameral devices for sustained delivery
US8313454B2 (en) * 1997-11-20 2012-11-20 Optonol Ltd. Fluid drainage device, delivery device, and associated methods of use and manufacture
WO2013082452A1 (fr) 2011-12-02 2013-06-06 Bioceptive, Inc. Procédés et appareil pour introduire un dispositif ou un produit pharmaceutique dans un utérus
WO2013116061A1 (fr) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Procédés et instrument pour l'insertion et le retrait de dispositifs thérapeutiques
US20140114323A1 (en) * 2010-06-10 2014-04-24 Hoya Corporation Ocular implant insertion apparatus and methods
US20140276901A1 (en) * 2012-06-04 2014-09-18 Altaviz, Llc Intraocular lens inserters
US20140303637A1 (en) * 2013-04-03 2014-10-09 Novartis Ag Automated intraocular lens injector device
US20140379079A1 (en) 2005-03-30 2014-12-25 Nulens Ltd. Accommodating intraocular lens having dual shape memory optical elements
US20150045805A1 (en) * 2011-09-16 2015-02-12 Medicontur Orvostechnikai Korlatolt Felelossrgu Tarsasag Device for injecting an intraocular lens into an eye
US9987163B2 (en) * 2013-04-16 2018-06-05 Novartis Ag Device for dispensing intraocular substances

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074052A2 (fr) 2001-03-16 2002-09-26 Glaukos Corporation Applicateur et procedes de mise en place de derivation trabeculaire pour traiter un glaucome
US20070060887A1 (en) * 2005-08-22 2007-03-15 Marsh David A Ophthalmic injector
US20080097335A1 (en) * 2006-08-04 2008-04-24 Allergan, Inc. Ocular implant delivery assemblies
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
WO2013022801A1 (fr) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Administration de petites molécules à l'aide d'un dispositif thérapeutique implantable
JP5907966B2 (ja) 2010-08-05 2016-04-26 フォーサイト・ビジョン フォー・インコーポレーテッド 埋め込み型治療デバイス
WO2012019139A1 (fr) 2010-08-05 2012-02-09 Forsight Vision4, Inc. Procédés et appareils d'administration combinée de médicament
AU2011285637B2 (en) 2010-08-05 2014-10-30 Forsight Vision4, Inc. Subconjunctival implant for posterior segment drug delivery
US20140033800A1 (en) 2010-11-11 2014-02-06 Forsight Vision4, Inc. Methods and apparatus to determine diffusion properties of porous structures for drug delivery
EP2640360A2 (fr) 2010-11-19 2013-09-25 Forsight Vision4, Inc. Formulations d'agents thérapeutiques pour des dispositifs implantés
WO2013003620A2 (fr) 2011-06-28 2013-01-03 Forsight Vision4, Inc. Procédés et appareil de diagnostic
EP3903733A1 (fr) 2011-09-16 2021-11-03 ForSight Vision4, Inc. Appareil d'échange de fluide
EP2968113B8 (fr) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systèmes pour l'administration intra-oculaire entretenue de composés à faible solubilité provenant d'un implant de système de pose d'orifice
CA2907681C (fr) 2013-03-28 2022-11-22 Forsight Vision4, Inc. Implant ophtalmique pour administrer des substances therapeutiques
US20160302965A1 (en) 2013-12-06 2016-10-20 Forsight Vision4, Inc. Implantable therapeutic devices
RU2695563C2 (ru) 2014-07-15 2019-07-24 Форсайт Вижн4, Инк. Способ и устройство для доставки глазного имплантата
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CN114587774A (zh) 2014-11-10 2022-06-07 弗赛特影像4股份有限公司 治疗眼睛的系统
KR20180084104A (ko) 2015-11-20 2018-07-24 포사이트 비젼4, 인크. 연장 방출 약물 전달 장치를 위한 다공성 구조물
AR108177A1 (es) 2016-04-05 2018-07-25 Forsight Vision4 Inc Dispositivos de suministro de fármacos oculares implantables

Patent Citations (490)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2585815A (en) 1947-01-16 1952-02-12 Mclintock Duncan Menzies Injection syringe
US2564977A (en) 1949-01-19 1951-08-21 Hu Quang Hsi Medical injecting apparatus
US3232117A (en) 1962-09-14 1966-02-01 Roger Gilmont Instr Inc Micrometer buret
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3618604A (en) 1969-06-09 1971-11-09 Alza Corp Ocular insert
US3641237A (en) 1970-09-30 1972-02-08 Nat Patent Dev Corp Zero order release constant elution rate drug dosage
US4034756A (en) 1971-01-13 1977-07-12 Alza Corporation Osmotically driven fluid dispenser
US3995635A (en) 1971-09-09 1976-12-07 Alza Corporation Ocular insert
US3828777A (en) 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3902495A (en) 1974-01-28 1975-09-02 Cavitron Corp Flow control system
US3961628A (en) 1974-04-10 1976-06-08 Alza Corporation Ocular drug dispensing system
US3949748A (en) 1974-09-26 1976-04-13 Oscar Malmin Injection syringe having aspirating and metering capabilities
US3949750A (en) 1974-10-07 1976-04-13 Freeman Jerre M Punctum plug and method for treating keratoconjunctivitis sicca (dry eye) and other ophthalmic aliments using same
US4135514A (en) 1974-12-23 1979-01-23 Alza Corporation Osmotic releasing system for administering ophthalmic drug to eye of animal
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US3977404A (en) 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4034758A (en) 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4014333A (en) 1975-09-22 1977-03-29 Mcintyre David J Instrument for aspirating and irrigating during ophthalmic surgery
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4014334A (en) 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4111201A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4220153A (en) 1978-05-08 1980-09-02 Pfizer Inc. Controlled release delivery system
US4220152A (en) 1978-05-08 1980-09-02 Pfizer Inc. Delivery system
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4298000A (en) 1978-11-08 1981-11-03 Minnesota Mining And Manufacturing Company Fluid dispensing device
US4300557A (en) 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4309776A (en) 1980-05-13 1982-01-12 Ramon Berguer Intravascular implantation device and method of using the same
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4484922A (en) 1981-06-25 1984-11-27 Rosenwald Peter L Occular device
US4475916A (en) 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4519801A (en) 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4673405A (en) 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4883459A (en) 1983-07-29 1989-11-28 Reynaldo Calderon Retrograde perfusion
US4627850A (en) 1983-11-02 1986-12-09 Alza Corporation Osmotic capsule
US4777049A (en) 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
US4712550A (en) 1985-04-08 1987-12-15 Sinnett Kevin B Retinal tack
US4609374A (en) 1985-04-22 1986-09-02 Alza Corporation Osmotic device comprising means for governing initial time of agent release therefrom
US4693886A (en) 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
US4737150A (en) 1985-05-10 1988-04-12 Intermedicat Gmbh Two-cannula syringe
US4781675A (en) 1985-11-27 1988-11-01 White Thomas C Infusion cannula
EP0228185B1 (fr) 1985-11-27 1990-07-25 Thomas C. White Dispositif implantable dans les tissus humains pour disperser des liquides
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5322691A (en) 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
EP0295248B2 (fr) 1986-12-23 1999-04-28 The Liposome Company, Inc. Preparation antibiotique a base de liposomes
WO1988004573A1 (fr) 1986-12-23 1988-06-30 The Liposome Company, Inc. Preparation antibiotique a base de liposomes
EP0498471A2 (fr) 1986-12-23 1992-08-12 The Liposome Company, Inc. Liposomes contenant un guanidino-aminoglycoside
EP0500143A2 (fr) 1986-12-23 1992-08-26 The Liposome Company, Inc. Composition pharmaceutique à base de phosphate d'aminoglycoside
US4865846A (en) 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US5174999A (en) 1988-12-13 1992-12-29 Alza Corporation Delivery system comprising fluid ingress and drug egress
WO1990007545A2 (fr) 1988-12-30 1990-07-12 Anderson David M Matieres microporeuses et matieres d'hydrogel stabilisees
US5098443A (en) 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5413572A (en) 1990-04-02 1995-05-09 Alza Corporation Osmotic dosage system for liquid drug delivery
US5128145A (en) 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
US5084021A (en) 1990-11-02 1992-01-28 Baldwin Brian E Patient controlled infusion apparatus and method
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5277912A (en) 1991-04-05 1994-01-11 Eli Lilly And Company Sustained release capsule and formulations
US5562915A (en) 1991-04-05 1996-10-08 Eli Lilly And Company Sustained release capsule and formulations
US5334189A (en) 1991-06-03 1994-08-02 Wade Stephen E Device for controlled diffusion of a chemical substance
US5282829A (en) 1991-08-15 1994-02-01 United States Surgical Corporation Hollow body implants
US5830546A (en) 1991-10-03 1998-11-03 Holvis Holzstoff S.A. Reservoir system for prolonged diffusion of an active principle
US5681572A (en) 1991-10-18 1997-10-28 Seare, Jr.; William J. Porous material product and process
US5178622A (en) 1991-11-01 1993-01-12 Lehner Ii Robert H Instrument for implanting a soft intraocular lens
US5300114A (en) 1992-05-04 1994-04-05 Allergan, Inc. Subconjunctival implants for ocular drug delivery
US5476511A (en) 1992-05-04 1995-12-19 Allergan, Inc. Subconjunctival implants for ocular drug delivery
US7026329B2 (en) 1992-09-21 2006-04-11 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US5766242A (en) 1993-11-15 1998-06-16 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5824072A (en) 1993-11-15 1998-10-20 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5807581A (en) 1994-02-09 1998-09-15 Collagen Corporation Collagen-based injectable drug delivery system and its use
EP0671165A2 (fr) 1994-02-09 1995-09-13 Collagen Corporation Système injectable pour la délivrance d'un médicament à base de collagène et son utilisation
US5770076A (en) 1994-03-07 1998-06-23 The Regents Of The University Of California Micromachined capsules having porous membranes and bulk supports
US5985328A (en) 1994-03-07 1999-11-16 Regents Of The University Of California Micromachined porous membranes with bulk support
US5516522A (en) 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
WO1995028984A1 (fr) 1994-04-25 1995-11-02 Escalon Ophthalmics, Inc. Pointe pour l'administration intraoculaire de medicaments et procede permettant d'introduire et d'enlever ladite pointe
US5916584A (en) 1994-10-25 1999-06-29 Daratech Proprietary Limited Controlled release container with core and outer shell
US5836935A (en) 1994-11-10 1998-11-17 Ashton; Paul Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5830173A (en) 1994-12-12 1998-11-03 Avery; Robert Logan Intravitreal medicine delivery
US5554132A (en) 1995-03-30 1996-09-10 Abbott Laboratories Hand grip for use with syringe
US5868697A (en) 1995-05-14 1999-02-09 Optonol Ltd. Intraocular implant
US5702414A (en) 1995-05-14 1997-12-30 Optonol Ltd Method of implanting an intraocular implant
US6096070A (en) 1995-06-07 2000-08-01 Med Institute Inc. Coated implantable medical device
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6001386A (en) 1995-09-27 1999-12-14 University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US20040011651A1 (en) 1996-01-31 2004-01-22 Board Of Regents, The University Of Texas System Method and apparatus for fractionation using conventional dielectrophoresis and field flow fractionation
WO1997029850A1 (fr) 1996-02-15 1997-08-21 Nomix-Chipman Limited Pistolet pulverisateur
US20090005864A1 (en) 1996-03-18 2009-01-01 Eggleston Harry C Modular intraocular implant
US5951512A (en) 1996-05-28 1999-09-14 Horizon Medical Products, Inc. Infusion port with modified drug reservoir
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US6123861A (en) 1996-07-02 2000-09-26 Massachusetts Institute Of Technology Fabrication of microchip drug delivery devices
US5928662A (en) 1996-07-31 1999-07-27 Phillips; Andrew F. Ocular drug delivery device
EP0944658B1 (fr) 1996-12-13 2003-06-25 Novartis AG Polymeres de polyorganosiloxane poreux
WO1998025982A1 (fr) 1996-12-13 1998-06-18 Novartis Ag Polymeres de polyorganosiloxane poreux
US6663668B1 (en) 1996-12-13 2003-12-16 Novartis Ag Hydratable siloxane comprising porous polymers
US5972369A (en) 1997-03-31 1999-10-26 Alza Corporation Diffusional implantable delivery system
US7476510B2 (en) 1997-05-29 2009-01-13 Cellomics, Inc. Miniaturized cell array methods and apparatus for cell-based screening
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6039712A (en) 1997-11-04 2000-03-21 Terence M. Fogarty Implantable injection port
US8313454B2 (en) * 1997-11-20 2012-11-20 Optonol Ltd. Fluid drainage device, delivery device, and associated methods of use and manufacture
US6196993B1 (en) 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US6605066B1 (en) 1998-09-18 2003-08-12 Imedex Biomateriaux Device for forming and delivering a mixture
US7973068B2 (en) 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
WO2000048660A1 (fr) 1999-02-18 2000-08-24 Alcove Surfaces Gmbh Implant
US6740077B1 (en) 1999-02-18 2004-05-25 Alcove Surfaces Gmbh Implant with permeable element
US7914442B1 (en) 1999-03-01 2011-03-29 Gazdzinski Robert F Endoscopic smart probe and method
US6932983B1 (en) 1999-05-27 2005-08-23 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6472162B1 (en) 1999-06-04 2002-10-29 Thermogenesis Corp. Method for preparing thrombin for use in a biological glue
US6420399B1 (en) 1999-06-18 2002-07-16 Alcon Manufacturing, Ltd. Topical ophthalmic mast cell stabilizers for treating allergic eye disease
WO2001026714A1 (fr) 1999-10-12 2001-04-19 Durect Corporation Regulation de la distribution d'un medicament par deviation de son trajet d'ecoulement
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
US6413540B1 (en) 1999-10-21 2002-07-02 Alcon Universal Ltd. Drug delivery device
US20050112175A1 (en) 1999-10-21 2005-05-26 Yoseph Yaacobi Drug delivery device
US20030003129A1 (en) 1999-10-21 2003-01-02 Yoseph Yaacobi Ophthalmic drug delivery device
US20040131654A1 (en) 1999-10-21 2004-07-08 Yoseph Yaacobi Ophthalmic drug delivery device
US20040131655A1 (en) 1999-10-21 2004-07-08 Yoseph Yaacobi Ophthalmic drug delivery device
US6669950B2 (en) 1999-10-21 2003-12-30 Alcon, Inc. Ophthalmic drug delivery device
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US20050119737A1 (en) 2000-01-12 2005-06-02 Bene Eric A. Ocular implant and methods for making and using same
WO2001050943A2 (fr) 2000-01-12 2001-07-19 Becton, Dickinson And Company Systemes et procedes permettant de reduire la pression intraoculaire
US20080161741A1 (en) 2000-01-12 2008-07-03 Becton, Dickinson And Company Ocular implant and methods for making and using same
US7077848B1 (en) 2000-03-11 2006-07-18 John Hopkins University Sutureless occular surgical methods and instruments for use in such methods
US20030005945A1 (en) 2000-03-13 2003-01-09 Hiroyuki Onishi Method for surface-treatment, surface-treated article and device for surface treatment
US7141152B2 (en) 2000-03-16 2006-11-28 Le Febre David A Analyte species separation system
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20020116009A1 (en) * 2000-05-08 2002-08-22 Fraser Robert D. Medical installation tool
US20020026176A1 (en) 2000-08-30 2002-02-28 Varner Signe Erickson Devices for intraocular drug delivery
US6719750B2 (en) 2000-08-30 2004-04-13 The Johns Hopkins University Devices for intraocular drug delivery
EP1337284B1 (fr) 2000-09-06 2007-12-05 Alcon Inc. Compositions de revetement a pouvoir adhesif variable pour implants ophtalmiques
US6303290B1 (en) 2000-09-13 2001-10-16 The Trustees Of The University Of Pennsylvania Encapsulation of biomaterials in porous glass-like matrices prepared via an aqueous colloidal sol-gel process
US6756049B2 (en) 2000-12-29 2004-06-29 Bausch & Lomb Incorporated Sustained release drug delivery devices
US20020110591A1 (en) 2000-12-29 2002-08-15 Brubaker Michael J. Sustained release drug delivery devices
US20020110592A1 (en) 2001-01-03 2002-08-15 Brubaker Michael J. Sustained release drug delivery devices with multiple agents
US20020086051A1 (en) 2001-01-03 2002-07-04 Santos Viscasillas Sustained release drug delivery devices with coated drug cores
US6756058B2 (en) 2001-01-03 2004-06-29 Bausch & Lomb Incorporated Sustained release drug delivery devices with multiple agents
US20020106395A1 (en) 2001-01-03 2002-08-08 Brubaker Michael J. Sustained release drug delivery devices with prefabricated permeable plugs
US20030212383A1 (en) 2001-01-05 2003-11-13 Dana Cote System and methods for reducing intraocular pressure
US6976982B2 (en) 2001-01-09 2005-12-20 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
US20020110635A1 (en) 2001-01-26 2002-08-15 Brubaker Michael J. Process for the production of sustained release drug delivery devices
US7181287B2 (en) 2001-02-13 2007-02-20 Second Sight Medical Products, Inc. Implantable drug delivery device
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US7883717B2 (en) 2001-06-12 2011-02-08 Johns Hopkins University Reservoir device for intraocular drug delivery
US20030014036A1 (en) 2001-06-12 2003-01-16 Varner Signe Erickson Reservoir device for intraocular drug delivery
US20110098686A1 (en) 2001-06-12 2011-04-28 Johns Hopkins University Reservoir Device for Intraocular Drug Delivery
US7195778B2 (en) 2001-07-10 2007-03-27 Teva Pharmaceutical Industries Ltd. Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US20040209359A1 (en) 2001-07-19 2004-10-21 Avner Yayon Plasma protein matrices and methods for their preparation
US20040092911A1 (en) 2001-07-23 2004-05-13 Yoseph Yaacobi Ophthalmic drug delivery device
EP1385452B1 (fr) 2001-07-23 2006-09-13 Alcon, Inc. Dispositif d'administration de medicament ophtalmique
US7094226B2 (en) 2001-07-23 2006-08-22 Alcon, Inc. Ophthalmic drug delivery device
US6986900B2 (en) 2001-07-23 2006-01-17 Alcon, Inc. Ophthalmic drug delivery device
EP1409065B1 (fr) 2001-07-23 2007-01-17 Alcon, Inc. Dispositif d'administration de medicament ophtalmique
US20040106906A1 (en) 2001-07-23 2004-06-03 Yoseph Yaacobi Opthalmic drug delivery device
US7195774B2 (en) 2001-08-29 2007-03-27 Carvalho Ricardo Azevedo Ponte Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues
US20050113806A1 (en) 2001-08-29 2005-05-26 De Carvalho Ricardo A.P. Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues
US20030118649A1 (en) 2001-10-04 2003-06-26 Jinming Gao Drug delivery devices and methods
US20100221309A1 (en) 2001-10-12 2010-09-02 Monosol Rx, Llc Film compositions for delivery of actives
US20030119177A1 (en) 2001-11-15 2003-06-26 Lewis Gruber Sample chip
US20060246112A1 (en) 2002-01-18 2006-11-02 Snyder Michael E Sustained release ophthalmological device and method of making and using the same
US20100022945A1 (en) 2002-03-11 2010-01-28 Theron Robert Rodstrom Implantable drug delivery system
WO2003077972A2 (fr) 2002-03-11 2003-09-25 Alcon, Inc. Systeme de distribution de medicament implantable
US20030176854A1 (en) 2002-03-11 2003-09-18 Alcon, Inc. Implantable drug delivery system
US7621907B2 (en) 2002-03-11 2009-11-24 Alcon, Inc. Implantable drug delivery system
WO2003082188A2 (fr) 2002-03-27 2003-10-09 Frank Kochinke Procedes et systemes d'administration de medicaments pour le traitement de maladies bucco-faciales
US7074426B2 (en) 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US20030185872A1 (en) 2002-03-27 2003-10-02 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
WO2004000267A1 (fr) 2002-06-19 2003-12-31 Scimed Life Sytems, Inc. Procede de modulation de liberation d'un medicament a partir de dispositifs medicaux multiphases a implanter ou a inserer et procede permettant de produire de tels dispositifs
US20030235603A1 (en) 2002-06-19 2003-12-25 Schwarz Marlene C. Multiphase polymeric drug release region
US7939094B2 (en) 2002-06-19 2011-05-10 Boston Scientific Scimed, Inc. Multiphase polymeric drug release region
EP1521572B1 (fr) 2002-07-15 2009-03-04 Alcon, Inc. Film bioeroable pour l'administration de medicaments ophtalmiques
US20100114017A1 (en) 2002-07-23 2010-05-06 Reverse Medical Corporation Systems and methods for removing obstructive matter from body lumens and treating vascular defects
US20040019325A1 (en) 2002-07-29 2004-01-29 Medrip Ltd. Syringe Pump
US20050154399A1 (en) 2002-09-18 2005-07-14 Allergan, Inc. Apparatus for delivery of ocular implants
US7090681B2 (en) 2002-09-18 2006-08-15 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US7468065B2 (en) 2002-09-18 2008-12-23 Allergan, Inc. Apparatus for delivery of ocular implants
US7753916B2 (en) * 2002-09-18 2010-07-13 Weber David A Methods and apparatus for delivery of ocular implants
US20050143363A1 (en) 2002-09-29 2005-06-30 Innorx, Inc. Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid of the retina; and related methods for treatment and/or prevention of retinal diseases
US20060200097A1 (en) 2003-01-24 2006-09-07 Doheny Retina Institute Reservoirs with subretinal cannula for subretinal drug delivery
US20040230183A1 (en) 2003-02-18 2004-11-18 Wisam Breegi Drug delivery device and syringe for filling the same
US20060258000A1 (en) 2003-02-26 2006-11-16 Allen Jared W Use of steady-state oxygen gradients to modulate animal cell functions
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050074497A1 (en) 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050276837A1 (en) 2003-05-02 2005-12-15 Anderson Aron B Controlled release bioactive agent delivery device
EP1671624A1 (fr) 2003-05-02 2006-06-21 SurModics, Inc. Un système bioactive pour la libération controlée d'un agent bioactif dans la section postérieure oculaire
US20050287188A1 (en) 2003-05-02 2005-12-29 Anderson Aron B Controlled release bioactive agent delivery device
US20050281863A1 (en) 2003-05-02 2005-12-22 Anderson Aron B Controlled release bioactive agent delivery device
US20050271706A1 (en) 2003-05-02 2005-12-08 Anderson Aron B Controlled release bioactive agent delivery device
US20050271703A1 (en) 2003-05-02 2005-12-08 Anderson Aron B Controlled release bioactive agent delivery device
US20060013835A1 (en) 2003-05-02 2006-01-19 Anderson Aron B Controlled release bioactive agent delivery device
US8403941B2 (en) 2003-06-02 2013-03-26 Abbott Medical Optics Inc. Intraocular lens and cartridge packaging with lens-loading function
US20040238392A1 (en) 2003-06-02 2004-12-02 Peterson Rod T. Intraocular lens and cartridge packaging with lens-loading function
US20050163711A1 (en) 2003-06-13 2005-07-28 Becton, Dickinson And Company, Inc. Intra-dermal delivery of biologically active agents
WO2005016401A2 (fr) 2003-06-13 2005-02-24 Becton Dickinson And Company Administration intradermique amelioree d'agents bioactifs
US20040260381A1 (en) 2003-06-18 2004-12-23 D-Crown Ltd Devices and methods for forming stenting structures in situ
US20040260380A1 (en) 2003-06-18 2004-12-23 D-Crown Ltd Devices for delivering multiple stenting structures in situ
WO2004112653A2 (fr) 2003-06-18 2004-12-29 D-Crown Ltd. Dispositifs et procedes pour l'apport et la formation in situ de structures d'endoprotheses individuelles et multiples
US20050112759A1 (en) 2003-06-20 2005-05-26 Milica Radisic Application of electrical stimulation for functional tissue engineering in vitro and in vivo
US20060039952A1 (en) 2003-07-10 2006-02-23 Yoseph Yaacobi Ophthalmic drug delivery device
US20070235331A1 (en) 2003-07-25 2007-10-11 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US20070141111A1 (en) 2003-08-20 2007-06-21 Bioretec Oy Porous medical device and method for its manufacture
US7252673B2 (en) * 2003-09-10 2007-08-07 Warsaw Orthopedic, Inc. Devices and methods for inserting spinal implants
US20050055031A1 (en) * 2003-09-10 2005-03-10 Roy Lim Devices and methods for inserting spinal implants
US20090324687A1 (en) 2003-09-18 2009-12-31 Macusight, Inc. Transscleral delivery
US20090324690A1 (en) 2003-09-18 2009-12-31 Macusight, Inc. Transscleral delivery
US7585517B2 (en) 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
US20050064010A1 (en) 2003-09-18 2005-03-24 Cooper Eugene R. Transscleral delivery
US20090324688A1 (en) 2003-09-18 2009-12-31 Macusight, Inc. Transscleral delivery
WO2005027906A1 (fr) 2003-09-18 2005-03-31 Macusight, Inc. Administration transsclerale d'agents therapeutiques
US20090324686A1 (en) 2003-09-18 2009-12-31 Macusight, Inc. Transscleral delivery
US20090324689A1 (en) 2003-09-18 2009-12-31 Macusight, Inc. Transscleral delivery
US20050181018A1 (en) 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
US7686016B2 (en) 2003-09-24 2010-03-30 Medi-Stream Pty Ltd Acn 111 815 715 Medication holder
WO2005028006A1 (fr) 2003-09-24 2005-03-31 Medi-Stream Pty Ltd Support pour medicament
US20070119450A1 (en) 2003-09-24 2007-05-31 Wharton David P Medication holder
US7615141B2 (en) 2003-10-03 2009-11-10 University Of Washington Electrochemical micromanufacturing system and method
US7211272B2 (en) 2003-12-22 2007-05-01 Bausch & Lomb Incorporated Drug delivery device
US20050277802A1 (en) 2004-02-12 2005-12-15 Larsen Charles E Method and apparatus for intraocular brachytherapy
US7276050B2 (en) 2004-03-02 2007-10-02 Alan Franklin Trans-scleral drug delivery method and apparatus
US20050256499A1 (en) 2004-03-03 2005-11-17 Pettis Ronald J Methods and devices for improving delivery of a substance to skin
WO2005091922A2 (fr) 2004-03-03 2005-10-06 Becton, Dickinson And Company Procedes et dispositifs pour l'amelioration de l'administration cutanee d'une substance
US20090124997A1 (en) 2004-03-03 2009-05-14 Becton, Dickinson And Company Methods and devices for improving delivery of a substance to skin
WO2005110473A2 (fr) 2004-04-09 2005-11-24 Directcontact Llc Procedes et articles d'administration de medicaments dans l'oeil en vue de traiter des maladies du segment posterieur
US20080097459A1 (en) 2004-04-22 2008-04-24 Advanced Vision Science, Inc. Device For The Insertion Of Deformable Intra-Ocular Lenses
WO2005110362A1 (fr) 2004-04-30 2005-11-24 Allergan, Inc. Implants oculaires biodegradables a caracteristiques de liberation a longue echeance
US20080241223A1 (en) 2004-04-30 2008-10-02 Allergan, Inc. Extended release biodegradable ocular implants
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244467A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended release biodegradable ocular implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
WO2005110436A2 (fr) 2004-04-30 2005-11-24 Allergan, Inc. Implants a liberation prolongee contenant des macromolecules et leurs procedes
US20080233173A1 (en) 2004-04-30 2008-09-25 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20080241221A1 (en) 2004-04-30 2008-10-02 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20110034448A1 (en) 2004-04-30 2011-02-10 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
WO2005107705A2 (fr) 2004-04-30 2005-11-17 Allergan, Inc. Traitements a base d'implants oculaires a effet therapeutique prolonge
US20080172014A1 (en) 2004-04-30 2008-07-17 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20080233171A1 (en) 2004-04-30 2008-09-25 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20080241220A1 (en) 2004-04-30 2008-10-02 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20080241222A1 (en) 2004-04-30 2008-10-02 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20050281861A1 (en) 2004-04-30 2005-12-22 Allergan, Inc. Macromolecule-containing sustained release intraocular implants and related methods
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20080233172A1 (en) 2004-04-30 2008-09-25 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20080241219A1 (en) 2004-04-30 2008-10-02 Allergan, Inc. Extended therapeutic effect ocular implant treatments
WO2005117780A2 (fr) 2004-06-01 2005-12-15 Becton, Dickinson And Company Implant oculaire et procedes de fabrication et d'utilisation associes
WO2006014484A2 (fr) 2004-07-02 2006-02-09 Surmodics, Inc. Procedes et dispositifs pour le traitement d'affections oculaires
US20060110428A1 (en) 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
US20110159073A1 (en) 2004-07-02 2011-06-30 Eugene Dejuan Methods and devices for the treatment of ocular conditions
US7117870B2 (en) 2004-07-26 2006-10-10 Clarity Corporation Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
WO2006015385A2 (fr) 2004-08-06 2006-02-09 Sopherion Therapeutics, Inc. Peptides anti-angiogènes et leurs procédés d'utilisation
US20090047335A1 (en) 2004-08-06 2009-02-19 Sopherion Therapeutics, Inc. Anti-angiogenic peptides and methods of use thereof
WO2006031358A2 (fr) 2004-08-13 2006-03-23 Hyperbranch Medical Technology, Inc. Polymeres dendritiques, gels reticules, et leurs utilisations comme agents de scellement et lentilles ophtalmiques
WO2006023530A2 (fr) 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions et procedes permettant d'ameliorer le systeme structurel et fonctionnel de la reorganisation et de la recuperation du systeme nerveux
US20060104969A1 (en) 2004-08-16 2006-05-18 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
WO2006031388A2 (fr) 2004-08-20 2006-03-23 Hyperbranch Medical Technology, Inc. Polymeres dendritiques et gels reticules: utilisations dans des applications orthopediques
US20060052754A1 (en) 2004-09-04 2006-03-09 Fields Douglas W Thumb trigger syringe pole
US20060057277A1 (en) 2004-09-10 2006-03-16 Chappa Ralph A Methods, devices, and coatings for controlled active agent release
US7709049B2 (en) 2004-09-10 2010-05-04 Surmodics, Inc. Methods, devices, and coatings for controlled active agent release
US20100083963A1 (en) 2004-09-24 2010-04-08 David Peter Wharton Medication holder
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US20060073182A1 (en) 2004-10-01 2006-04-06 Wong Vernon G Conveniently implantable sustained release drug compositions
US20110111006A1 (en) 2004-10-01 2011-05-12 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US7906136B2 (en) 2004-10-01 2011-03-15 Ramscor, Inc. Conveniently implantable sustained release drug compositions
WO2006044614A2 (fr) 2004-10-14 2006-04-27 Sopherion Therapeutics, Inc. Peptides anti-angiogeniques et procedes d'utilisation de ceux-ci
US20060172941A1 (en) 2004-10-14 2006-08-03 Luca Rastelli Anti-angiogenic peptides and methods of use thereof
US20080207502A1 (en) 2004-10-14 2008-08-28 Sopherion Therapeutics, Inc. Anti-Angiogenic Peptides and Methods of Use Thereof
US20100015157A1 (en) 2004-10-20 2010-01-21 Genentech, Inc. Antibody formulations
US20110014264A1 (en) 2004-12-09 2011-01-20 Boston Scientific Scimed, Inc. Medical Devices Having Nanostructured Regions For Controlled Tissue Biocompatibility And Drug Delivery
US20060129215A1 (en) 2004-12-09 2006-06-15 Helmus Michael N Medical devices having nanostructured regions for controlled tissue biocompatibility and drug delivery
WO2006068838A2 (fr) 2004-12-09 2006-06-29 Boston Scientific Scimed, Inc. Dispositifs medicaux comportant des regions nanostructurees pour une biocompatibilite tissulaire et une liberation de medicament controlees
WO2006071554A2 (fr) 2004-12-23 2006-07-06 Allergan, Inc. Appareil ameliore pour administrer des implants oculaires
US20060154981A1 (en) 2005-01-12 2006-07-13 Alcon, Inc. Method of reducing intraocular pressure and treating glaucoma
WO2006082588A2 (fr) 2005-02-07 2006-08-10 Pharmalight Inc. Procede et dispositif d'administration ophtalmique d'ingredients pharmaceutiquement actifs
US20080233053A1 (en) 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
US20060233858A1 (en) 2005-03-08 2006-10-19 Allergan, Inc. Systems and methods providing targeted intraocular drug delivery
US20060257450A1 (en) 2005-03-21 2006-11-16 Sreenivasu Mudumba Drug delivery systems for treatment of diseases or conditions
US20070077270A1 (en) 2005-03-28 2007-04-05 Clemson University Delivery devices and methods for long-term, targeted delivery of therapeutic agents to the eye and ear
US20140379079A1 (en) 2005-03-30 2014-12-25 Nulens Ltd. Accommodating intraocular lens having dual shape memory optical elements
WO2006108054A2 (fr) 2005-04-05 2006-10-12 The Ohio State University Systeme de distribution par diffusion et procedes de fabrication
US20060258994A1 (en) 2005-05-12 2006-11-16 Avery Robert L Implantable delivery device for administering pharmacological agents to an internal portion of a body
WO2006125106A1 (fr) 2005-05-18 2006-11-23 Surmodics, Inc. Instrument d'insertion destine aux dispositifs medicaux non lineaires
US20070088414A1 (en) 2005-05-25 2007-04-19 Campbell Robert L Particulate formulations for intradermal delivery of biologically active agents
WO2006127962A2 (fr) 2005-05-25 2006-11-30 Becton, Dickinson And Comapny Formulations particulaires pour une administration intradermique d'agents biologiquement actifs
US20060276738A1 (en) 2005-06-06 2006-12-07 Becker Bruce B Lacrimal drainage bypass device and method
US20110112188A1 (en) 2005-06-17 2011-05-12 Dynamis Therapeutics, Inc. Treatment of Inflammatory Conditions
WO2006138609A2 (fr) 2005-06-17 2006-12-28 Dynamis Therapeutics, Inc. Traitement d'etats inflammatoires
US20070021357A1 (en) 2005-06-17 2007-01-25 Dynamis Therapeutics, Inc. Treatment of inflammatory conditions
WO2007012974A2 (fr) 2005-07-22 2007-02-01 Oculis Ehf Nanotechnologie a base de cyclodextrine pour administration de medicaments ophtalmiques
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20070020336A1 (en) 2005-07-22 2007-01-25 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20070026037A1 (en) 2005-07-29 2007-02-01 Kloke Timothy M Devices, articles, coatings, and methods for controlled active agent release or hemocompatibility
US20070212397A1 (en) 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
WO2007035621A1 (fr) 2005-09-16 2007-03-29 (Osi) Eyetech, Inc. Seringue oculaire
US20080003219A1 (en) 2005-09-26 2008-01-03 Minu, L.L.C. Delivery of an ocular agent
WO2007038453A2 (fr) 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Administration d'un agent pour l'amelioration de l'inflammation
US20080167600A1 (en) 2005-09-26 2008-07-10 Peyman Gholam A Device for delivery of an agent to the eye and other sites
US20070071756A1 (en) 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an agent to ameliorate inflammation
US20070072933A1 (en) 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an ocular agent
US20100216702A1 (en) 2005-10-06 2010-08-26 Szkudlinski Mariusz W Vegf analogs and methods of use
WO2007044534A2 (fr) 2005-10-06 2007-04-19 Trophogen, Inc. Analogues du vegf et procedes d'utilisation
US20090043253A1 (en) 2005-10-11 2009-02-12 Blake Podaima Smart medical compliance method and system
US20070197491A1 (en) 2005-10-14 2007-08-23 Alcon, Inc. Method for treating primary and secondary forms of glaucoma
WO2007047744A2 (fr) 2005-10-14 2007-04-26 Alcon, Inc. Methode de traitement de la forme primaire et de la forme secondaire du glaucome
US20070128644A1 (en) 2005-12-01 2007-06-07 Canon Kabushiki Kaisha Fluid control method and fluid control apparatus
US20070134305A1 (en) 2005-12-07 2007-06-14 Ramot At Tel Aviv University Ltd. Drug-delivering composite structures
WO2007066339A1 (fr) 2005-12-07 2007-06-14 Ramot At Tel Aviv University Ltd. Structures composites pour l’administration de médicaments
US20070131610A1 (en) 2005-12-13 2007-06-14 General Electric Company Membrane-based apparatus and associated method
US20070131611A1 (en) 2005-12-13 2007-06-14 General Electric Company Membrane-based article and associated method
US20070191863A1 (en) 2006-01-17 2007-08-16 De Juan Eugene Jr Glaucoma Treatment Device
US20070233037A1 (en) 2006-01-17 2007-10-04 Gifford Hanson S Iii Drug Delivery Treatment Device
WO2007084582A2 (fr) 2006-01-17 2007-07-26 Forsight Labs, Llc Dispositif de traitement d’administration de medicament
US20080216736A1 (en) 2006-01-19 2008-09-11 Takeda San Diego, Inc. Microfluidic device with diffusion between adjacent lumens
WO2007084765A2 (fr) 2006-01-19 2007-07-26 Potentia Pharmaceuticals, Inc. Traitement combinatoire injectable destine a des troubles ophtalmiques
US20090280470A1 (en) 2006-02-24 2009-11-12 Rosetta Inpharmatics Llc Extraction and diagnostic fluid devices, systems and methods of use
US20070203174A1 (en) 2006-02-27 2007-08-30 Alcon Manufacturing, Ltd. Method of treating glaucoma
WO2007101204A1 (fr) 2006-02-27 2007-09-07 Alcon Research, Ltd. Méthode de traitement du glaucome
US7625927B2 (en) 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
US20100297046A1 (en) 2006-03-31 2010-11-25 Dynamis Therapeutics, Inc. Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors
WO2007117394A2 (fr) 2006-03-31 2007-10-18 Dynamis Therapeutics, Inc. Compositions et procedes relatifs aux inhibiteurs de la fructosamine-3-kinase
US20090092654A1 (en) 2006-03-31 2009-04-09 Qlt Plug Delivery, Inc. Drug Delivery Methods, Structures, and Compositions for Nasolacrimal System
US20070269487A1 (en) 2006-03-31 2007-11-22 Forsight Labs, Llc Drug Delivery Methods, Structures, and Compositions for Nasolacrimal System
US20070243230A1 (en) 2006-03-31 2007-10-18 Forsight Labs, Llc Nasolacrimal Drainage System Implants for Drug Therapy
US20100168535A1 (en) 2006-04-12 2010-07-01 Mark Ries Robinson Methods and apparatuses related to blood analyte measurement system
US20090326448A1 (en) 2006-04-18 2009-12-31 Pingan Huo Sterile Drug-Mixing Syringe
US20100256597A1 (en) 2006-05-02 2010-10-07 Emory University Methods and Devices for Drug Delivery to Ocular Tissue Using Microneedle
WO2007131050A2 (fr) 2006-05-02 2007-11-15 Georgia Tech Research Corporation Méthode d'administration de médicament dans les tissus oculaires par micro-aiguille
US20070260201A1 (en) 2006-05-02 2007-11-08 Georgia Tech Research Corporation Method for drug delivery to ocular tissue using microneedle
WO2007133761A2 (fr) 2006-05-15 2007-11-22 Momentive Performance Materials Inc. Appareil à membrane et procédé associé
WO2007133762A1 (fr) 2006-05-15 2007-11-22 Momentive Performance Materials Inc. Article à membrane et procédé associé
US20080124372A1 (en) 2006-06-06 2008-05-29 Hossainy Syed F A Morphology profiles for control of agent release rates from polymer matrices
WO2008003043A2 (fr) 2006-06-28 2008-01-03 Surmodics, Inc. Matrice dégradable et matrice non dégradable en association pour la libération d'un agent actif
US20080020045A1 (en) 2006-06-28 2008-01-24 Chappa Ralph A Combination Degradable and Non-Degradable Matrices for Active Agent Delivery
US20080004329A1 (en) 2006-06-29 2008-01-03 Jazz Pharmaceuticals Pharmaceutical compositions of ropinirole and methods of use thereof
WO2008005240A2 (fr) 2006-06-29 2008-01-10 Jazz Pharmaceuticals Compositions pharmaceutiques de ropinirole et leurs méthodes d'application
US20100100104A1 (en) 2006-06-30 2010-04-22 Aquesys, Inc. Systems for reducing pressure in an organ
US20100011888A1 (en) 2006-07-19 2010-01-21 Janusz Pawliszyn Method and device to extract components contained in a fluid
WO2008011125A2 (fr) 2006-07-20 2008-01-24 Neurosystec Corporation Dispositifs, systèmes et procédés destinés à administrer des médicaments ophtalmiques
US20080152694A1 (en) 2006-07-20 2008-06-26 Neurosystec Corporation Devices, Systems and Methods for Ophthalmic Drug Delivery
US20080069854A1 (en) 2006-08-02 2008-03-20 Inframat Corporation Medical devices and methods of making and using
US20080057561A1 (en) 2006-08-29 2008-03-06 Canon Kabushiki Kaisha Cell culture treatment apparatus and cell culture treatment method
WO2008033924A2 (fr) 2006-09-12 2008-03-20 Board Of Regents Of The University Of Nebraska Méthodes et compositions pour l'administration ciblée d'agents thérapeutiques
US20090087494A1 (en) 2006-09-12 2009-04-02 Board Of Regents Of The University Of Nebraska Methods and Compositions for Targeted Delivery of Therapeutic Agents
US20080066741A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
EP1911481A2 (fr) 2006-09-20 2008-04-16 Next Safety, Inc. Procédés et systèmes de fourniture de médicaments par inhalation
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US20080089923A1 (en) 2006-09-29 2008-04-17 Burkstrand Michael J Biodegradable ocular implants and methods for treating ocular conditions
WO2008060359A2 (fr) 2006-09-29 2008-05-22 Surmodics, Inc. Implants oculaires biodégradables, et procédés pour traiter des maladies de l'œil
WO2008040062A1 (fr) 2006-10-05 2008-04-10 Medi-Stream Pty Ltd Dispositif pour médicament
WO2008045272A2 (fr) 2006-10-06 2008-04-17 Dynamis Therapeutics, Inc. Compositions et procédés éclaircissante pour la peau
US20100030136A1 (en) 2006-10-16 2010-02-04 Bruno Dacquay Ophthalmic Injection Device Including Dosage Control Device
US20080139674A1 (en) 2006-10-25 2008-06-12 Revalesio Corporation Methods of wound care and treatment
WO2008052145A2 (fr) 2006-10-25 2008-05-02 Revalesio Corporation Procédés de traitement thérapeutique des yeux et d'autres tissus humains à l'aide d'une solution enrichie en oxygène
US20100028442A1 (en) 2006-10-25 2010-02-04 Revalesio Corporation Methods of therapeutic treatment of eyes
US20110081384A1 (en) 2006-10-25 2011-04-07 Revalesio Corporation Methods of wound care and treatment
US20100021464A1 (en) 2006-10-25 2010-01-28 Revalesio Corporation Methods of wound care and treatment
US20080146679A1 (en) 2006-10-25 2008-06-19 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US20100297193A1 (en) 2006-10-25 2010-11-25 Revalesio Corporation Methods of therapeutic treatment of eyes
WO2008115290A2 (fr) 2006-10-25 2008-09-25 Revalesio Corporation Méthodes de soins et de traitement de plaies
US20080111282A1 (en) 2006-11-10 2008-05-15 Baojun Xie Process for Making Three Dimensional Objects From Dispersions of Polymer Colloidal Particles
WO2008061043A2 (fr) 2006-11-10 2008-05-22 Glaukos Corporation Dérivation uvéosclérale et procédés pour son implantation
US20080228127A1 (en) 2006-11-10 2008-09-18 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US20100286791A1 (en) 2006-11-21 2010-11-11 Goldsmith David S Integrated system for the ballistic and nonballistic infixion and retrieval of implants
US20090263346A1 (en) 2006-12-05 2009-10-22 David Taft Systems and methods for delivery of drugs
US20110009571A1 (en) 2006-12-05 2011-01-13 David Taft Systems and methods for delivery of materials
US20080154241A1 (en) 2006-12-07 2008-06-26 Burkstrand Michael J Latent stabilization of bioactive agents releasable from implantable medical articles
US20080147021A1 (en) 2006-12-15 2008-06-19 Jani Dharmendra M Drug delivery devices
WO2008076544A2 (fr) 2006-12-18 2008-06-26 Alcon Research, Ltd. Dispositifs et procédés pour l'administration de médicaments ophtalmiques
US20080145406A1 (en) 2006-12-18 2008-06-19 Alcon Manufacturing Ltd. Devices and methods for ophthalmic drug delivery
US20100266664A1 (en) 2006-12-18 2010-10-21 Alcon Research, Ltd. Devices And Methods For Ophthalmic Drug Delivery
US20100114309A1 (en) 2006-12-26 2010-05-06 De Juan Jr Eugene Drug delivery implants for inhibition of optical defects
US20100010452A1 (en) 2007-01-09 2010-01-14 Fovea Pharmaceuticals Apparatus for intra-ocular injection
US20080213611A1 (en) 2007-01-19 2008-09-04 Cinvention Ag Porous, non-degradable implant made by powder molding
WO2008094989A2 (fr) 2007-01-31 2008-08-07 Alcon Research, Ltd. Bouchons ponctuels et procédés d'administration d'agents thérapeutiques
US20080181930A1 (en) 2007-01-31 2008-07-31 Alcon Research, Ltd. Punctal Plugs and Methods of Delivering Therapeutic Agents
US20080200922A1 (en) 2007-02-16 2008-08-21 Brown David C Apparatus for inserting flexible medical implant
WO2008116165A2 (fr) 2007-03-21 2008-09-25 Next Safety, Inc. Procédés et systèmes d'administration d'une médication par inhalation
US20080249501A1 (en) 2007-04-09 2008-10-09 Medtronic Vascular, Inc. Methods for Simultaneous Injection and Aspiration of Fluids During a Medical Procedure
US20080286338A1 (en) 2007-05-15 2008-11-20 Boston Foundation For Sight Drug delivery system with scleral lens
WO2008144340A2 (fr) 2007-05-15 2008-11-27 Boston Foundation For Sight Système de distribution de médicament comprenant une lentille sclérale
US20080292679A1 (en) 2007-05-24 2008-11-27 Allergan, Inc. Biodegradable drug delivery system
WO2008144919A1 (fr) 2007-05-29 2008-12-04 Angiochem, Inc. Polypeptides de type aprotinine pour administrer à des tissus des agents conjugués à ceux-ci
US20100297120A1 (en) 2007-05-29 2010-11-25 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2009012075A1 (fr) 2007-07-16 2009-01-22 Alcon, Inc. Utilisation d'agents abaissant iop pour traiter des formes primaires et secondaires de glaucome
US20090036827A1 (en) 2007-07-31 2009-02-05 Karl Cazzini Juxtascleral Drug Delivery and Ocular Implant System
US7909800B2 (en) 2007-07-31 2011-03-22 Alcon Research, Ltd. Juxtascleral drug delivery and ocular implant system
WO2009023615A1 (fr) 2007-08-10 2009-02-19 Trustees Of Tufts College Compositions de soie tubulaires et procédés d'utilisation de celles-ci
US20090099626A1 (en) 2007-09-07 2009-04-16 Qlt Plug Delivery, Inc. - Qpdi Lacrimal implant detection
US20090104243A1 (en) 2007-09-07 2009-04-23 Qlt Plug Delivery, Inc. - Qpdi Drug cores for sustained release of therapeutic agents
US20090105749A1 (en) 2007-09-07 2009-04-23 Qlt Plug Delivery, Inc. - Qpdi Insertion and extraction tools for lacrimal implants
US20090082631A1 (en) 2007-09-24 2009-03-26 Cronin Michael D Elliptical retractor
US20090214601A1 (en) 2007-09-28 2009-08-27 Chappa Ralph A Porous Drug Delivery Devices and Related Methods
WO2009046164A1 (fr) 2007-10-05 2009-04-09 Tyco Healthcare Group Lp Ancrage d'étanchéité pour une utilisation dans des procédures chirurgicales
US20090093752A1 (en) 2007-10-05 2009-04-09 Tyco Healthcare Group Lp Seal anchor for use in surgical procedures
US20100316723A1 (en) 2007-10-25 2010-12-16 Revalesio Corporation Compositions and methods for treating inflammation
US20090247458A1 (en) 2007-10-25 2009-10-01 Revalesio Corporation Compositions and methods for treating cystic fibrosis
US20100008997A1 (en) 2007-10-25 2010-01-14 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
US20100009008A1 (en) 2007-10-25 2010-01-14 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US20090274771A1 (en) 2007-10-25 2009-11-05 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
US20090274730A1 (en) 2007-10-25 2009-11-05 Revalesio Corporation Compositions and methods for treating inflammation
US20090263495A1 (en) 2007-10-25 2009-10-22 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
WO2009055671A1 (fr) 2007-10-25 2009-04-30 Revalesio Corporation Compositions et procédés destinés au traitement de la fibrose kystique
WO2009055729A1 (fr) 2007-10-25 2009-04-30 Revalesio Corporation Compositions et procédés pour traiter une inflammation
WO2009055620A1 (fr) 2007-10-25 2009-04-30 Revalesio Corporation Compositions bactériostatiques ou bactériocides et procédés
WO2009055824A1 (fr) 2007-10-25 2009-04-30 Revalesio Corporation Compositions et procédés de traitement d'asthme et de troubles pulmonaires
US20100303917A1 (en) 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for treating cystic fibrosis
US20100028443A1 (en) 2007-10-25 2010-02-04 Revalesio Corporation Compositions and methods for treating inflammation
US20100303918A1 (en) 2007-10-25 2010-12-02 Revalesio Corporation Compositions and methods for treating asthma and other lung disorders
US20100310665A1 (en) 2007-10-25 2010-12-09 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US20100004189A1 (en) 2007-10-25 2010-01-07 Revalesio Corporation Compositions and methods for treating cystic fibrosis
WO2009061607A2 (fr) 2007-11-05 2009-05-14 Bausch & Lomb Incorporated Matières non miscibles à l'eau en tant que véhicules pour l'administration d'un médicament
US20100286121A1 (en) 2007-11-05 2010-11-11 Rohrs Brian R Water-Immiscible Materials as Vehicles for Drug Delivery
WO2009073192A2 (fr) 2007-12-04 2009-06-11 Landec Corporation Systèmes et procédés pour délivrer des substances
US20090240215A1 (en) 2007-12-20 2009-09-24 Mark Humayun Apparatus and methods for delivering therapeutic agents
WO2009086112A2 (fr) 2007-12-20 2009-07-09 University Of Southern California Appareil et procédés pour distribuer des agents thérapeutiques
US20090234449A1 (en) 2007-12-27 2009-09-17 De Juan Jr Eugene Intraocular, accommodating lens and methods of use
WO2009089409A2 (fr) 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Système d'injection intravitréen à canules coaxiales et son utilisation
WO2009094466A2 (fr) 2008-01-22 2009-07-30 University Of Florida Research Foundation, Inc. Lentilles de contact pour une libération prolongée d'agents bioactifs contenant des atténuateurs de diffusion
US20100330146A1 (en) 2008-01-22 2010-12-30 University Of Florida Research Foundation Inc. Contact lenses for extended release of bioactive agents containing diffusion attenuators
US20090224064A1 (en) 2008-03-10 2009-09-10 Vapore, Inc. Low Energy Vaporization of Liquids: Apparatus and Methods
WO2009112878A1 (fr) 2008-03-11 2009-09-17 Raouf Rekik Administration de médicament aux segments antérieur et postérieur de l'œil à l'aide de gouttes ophtalmiques
US20110104155A1 (en) 2008-03-11 2011-05-05 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye using eye drops
WO2009117112A2 (fr) 2008-03-21 2009-09-24 Novartis Ag Appareil de dispersion de poudre, procédé de fabrication et d’utilisation de l’appareil, composants pouvant être utilisés sur l’appareil et d’autres dispositifs, et divers agents actifs
WO2009124096A1 (fr) 2008-03-31 2009-10-08 Altea Therapeutics Corporation Système d’administration de perméant et procédés d'utilisation de celui-ci
WO2010008424A2 (fr) 2008-04-04 2010-01-21 Novartis Ag Dispositif de production d’aérosols
US20110108025A1 (en) 2008-04-04 2011-05-12 Nektar Therapeutics Aerosolization device
US20090258069A1 (en) 2008-04-15 2009-10-15 John Burnier Delivery of LFA-1 antagonists to the gastrointestinal system
WO2009128932A1 (fr) 2008-04-15 2009-10-22 Sarcode Corporation Administration d'antagonistes de lfa-1 au système gastro-intestinal
CN102098993A (zh) 2008-04-25 2011-06-15 加利福尼亚大学董事会 储藏并注入角膜移植物的装置
US20100034870A1 (en) 2008-04-30 2010-02-11 QLT. Plug Delivery, Inc. Composite lacrimal insert and related methods
WO2009134929A2 (fr) 2008-05-01 2009-11-05 Revalesio Corporation Compositions et méthodes de traitement de troubles digestifs
US20100003333A1 (en) 2008-05-01 2010-01-07 Revalesio Corporation Compositions and methods for treating digestive disorders
US20090281621A1 (en) 2008-05-07 2009-11-12 Becker Bruce B Punctal anchor for lacrimal stent, introducer tool and method
WO2009137777A2 (fr) 2008-05-08 2009-11-12 Replenish Pumps, Llc Dispositifs implantables d'administration de médicaments, et appareils et procédés de remplissage de ces dispositifs
US20100197512A1 (en) 2008-07-11 2010-08-05 Intellicyt Multi-Sample Particle Analyzer and Method for High Throughput Screening
US20100016786A1 (en) 2008-07-21 2010-01-21 Arstasis, Inc. Devices, methods, and kits for forming tracts in tissue
US20100023033A1 (en) 2008-07-25 2010-01-28 Medtronic Vescular, Inc. Hydrodynamic Thrombectomy Catheter
US20100022943A1 (en) 2008-07-25 2010-01-28 Medtronic Vascular, Inc. Hydrodynamic Thrombectomy Catheter
US20110206646A1 (en) 2008-08-19 2011-08-25 Zeni Alfonso Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
WO2010021993A1 (fr) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Procédés d'utilisation de cellules issues du tissu adipeux dans le traitement du système lymphatique et d'une maladie maligne
US7678078B1 (en) 2008-10-21 2010-03-16 KMG Pharma LLC Intravitreal injection device, system and method
US20100100054A1 (en) 2008-10-21 2010-04-22 Michel Cormier Intravitreal injection device and system
WO2010047753A1 (fr) 2008-10-21 2010-04-29 KMG Pharma LLC Dispositif, système et méthode d'injection intravitréenne
WO2010062628A1 (fr) 2008-10-27 2010-06-03 Revalesio Corporation Compositions et procédés pour traiter l’asthme et d’autres troubles pulmonaires
WO2010066714A1 (fr) 2008-12-09 2010-06-17 Pari Pharma Gmbh Dispositif d'aérosolthérapie
WO2010075565A2 (fr) 2008-12-23 2010-07-01 Reverse Medical Corporation Systèmes et procédés d'extraction de matières obstruantes de lumens corporels et de traitement de défauts vasculaires
US20100174272A1 (en) 2009-01-02 2010-07-08 Weiner Alan L In-situ refillable ophthalmic implant
WO2010078063A1 (fr) 2009-01-02 2010-07-08 Alcon Research, Ltd. Implant ophtalmique rechargeable in situ
WO2010080987A2 (fr) 2009-01-09 2010-07-15 Becker Bruce B Filière d'intubation lacrymale côte à côte et procédé
US20100185205A1 (en) 2009-01-16 2010-07-22 Allergan, Inc. Interocular injector
US8399006B2 (en) 2009-01-29 2013-03-19 Forsight Vision4, Inc. Posterior segment drug delivery
US20120029445A1 (en) 2009-01-29 2012-02-02 Forsight Vision4, Inc. Posterior segment drug delivery
US20120029470A1 (en) 2009-01-29 2012-02-02 Forsight Vision4, Inc. Posterior segment drug delivery
WO2010088548A1 (fr) 2009-01-29 2010-08-05 Forsight Labs, Llc Administration d'un médicament dans le segment postérieur
US20100255061A1 (en) 2009-01-29 2010-10-07 Forsight Labs, Llc Posterior Segment Drug Delivery
WO2010093945A2 (fr) 2009-02-13 2010-08-19 Glaukos Corporation Implant médicamenteux uvéoscléral et ses procédés d'implantation
WO2010095940A2 (fr) 2009-02-20 2010-08-26 To-Bbb Holding B.V. Sustème d'administration de médicament à base de glutathionne
US20100241102A1 (en) 2009-03-23 2010-09-23 Colin Ma Intravitreal injection devices and methods of injecting a substance into the vitreous chamber of the eye
WO2010125416A1 (fr) 2009-04-27 2010-11-04 Raouf Rekik Administration de médicaments dans le segment antérieur et le segment postérieur de l'oeil
WO2010126908A1 (fr) 2009-04-27 2010-11-04 Revalesio Corporation Compositions et procédés pour le traitement de la résistance à l'insuline et du diabète
US20100310664A1 (en) 2009-04-27 2010-12-09 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US20110125178A1 (en) 2009-05-15 2011-05-26 Michael Drews Devices, methods and kits for forming tracts in tissue
WO2010135369A1 (fr) 2009-05-18 2010-11-25 Dose Medical Corporation Implant oculaire à élution de médicament
WO2010141729A1 (fr) 2009-06-03 2010-12-09 Forsight Labs, Llc Distribution de médicament de segment antérieur
WO2010147661A1 (fr) 2009-06-16 2010-12-23 KMG Pharma LLC Dispositif et système d'injection intravitréenne
WO2011008897A2 (fr) 2009-07-14 2011-01-20 Board Of Regents, The University Of Texas System Procédés de réalisation de dispositifs à libération contrôlée avec une cinétique d'ordre zéro
WO2011008896A2 (fr) 2009-07-14 2011-01-20 Board Of Regents, The University Of Texas System Méthodes thérapeutiques utilisant des dispositifs d'administration contrôlée avec une cinétique d'ordre zéro
US20110033933A1 (en) 2009-07-15 2011-02-10 Morteza Gharib Method applying hemodynamic forcing and klf2 to initiate the growth and development of cardiac valves
US20110117083A1 (en) 2009-08-14 2011-05-19 Genentech, Inc. Biological markers for monitoring patient response to vegf antagonists
WO2011028850A1 (fr) 2009-09-01 2011-03-10 Northwestern University Distribution d'agents thérapeutiques à l'aide de nanoparticules modifiées par oligonucléotides en tant que véhicules
WO2011034627A2 (fr) 2009-09-21 2011-03-24 Harvard Bioscience, Inc. Procédés et appareils pour introduire des cellules dans un site tissulaire
US20120245505A1 (en) 2009-12-16 2012-09-27 Robinson Michael R Intracameral devices for sustained delivery
WO2011079232A1 (fr) 2009-12-23 2011-06-30 Psivida Us, Inc. Dispositifs d'administration à libération prolongée
US20110196317A1 (en) 2010-02-05 2011-08-11 Victor Lust Implantation instruments, system, and kit for punctal implants
US20140114323A1 (en) * 2010-06-10 2014-04-24 Hoya Corporation Ocular implant insertion apparatus and methods
US8905963B2 (en) 2010-08-05 2014-12-09 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
WO2012019136A2 (fr) 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Appareil d'injection et procédé d'administration de médicament
US20150045805A1 (en) * 2011-09-16 2015-02-12 Medicontur Orvostechnikai Korlatolt Felelossrgu Tarsasag Device for injecting an intraocular lens into an eye
WO2013082452A1 (fr) 2011-12-02 2013-06-06 Bioceptive, Inc. Procédés et appareil pour introduire un dispositif ou un produit pharmaceutique dans un utérus
US20140326249A1 (en) * 2011-12-02 2014-11-06 Bioceptive, Inc. Methods and apparatus for inserting a device or pharmaceutical into a uterus
WO2013116061A1 (fr) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Procédés et instrument pour l'insertion et le retrait de dispositifs thérapeutiques
US20150080846A1 (en) 2012-02-03 2015-03-19 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US20140276901A1 (en) * 2012-06-04 2014-09-18 Altaviz, Llc Intraocular lens inserters
US20140303637A1 (en) * 2013-04-03 2014-10-09 Novartis Ag Automated intraocular lens injector device
US9987163B2 (en) * 2013-04-16 2018-06-05 Novartis Ag Device for dispensing intraocular substances

Non-Patent Citations (58)

* Cited by examiner, † Cited by third party
Title
Andrews, "Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa," Am J Physiol. Apr. 1994;266(4 Pt 1):G657-664.
Avery et al., "Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy," Ophthalmology. Oct. 2006, 113(10):1695-1705.e6.
Bakri et al., "The effect of intravitreal triamcinolone acetonide on intraocular pressure," Ophthalmic Surgery, Lasers and Imaging, Sep./Oct. 2003; 34(5): 386-390.
Bird et al., Transport Phenomena, John Wiley & Sons, Inc., New York, 1960, pp. 196-201.
Block et al., "Solubility and dissolution of triamcinolone acetonide," Journal of Pharmaceutical Sciences,Apr. 1963; 62(4):617-621.
Castro et al., "Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization," Exp Eye Res. Aug. 2004;79(2):275-285.
Chirila et al., "The Vitreous Humor" in Handbook of Biomaterial Properties, eds. Black & Hastings. Chapman & Hall, London, 1998; pp. 125-131.
Cousins et al., "Program # 1251-Targeting Complement Factor 5 in Combination with Vascular Endothelial Growth Factor (VEGF) Inhibition for Neovascular Age Related Macular Degeneration (AMD): Results of a Phase 1 Study," [Presentation Abstract], AMD Clinical Trials Session # 220, May 3, 2010. 2 pages.
Cousins et al., "Program # 1251—Targeting Complement Factor 5 in Combination with Vascular Endothelial Growth Factor (VEGF) Inhibition for Neovascular Age Related Macular Degeneration (AMD): Results of a Phase 1 Study," [Presentation Abstract], AMD Clinical Trials Session # 220, May 3, 2010. 2 pages.
Deissler et al., "VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells,"Br J Ophthalmol 2008;92:839-843.
Donoso et al., "The role of inflammation in the pathogenesis of age-related macular degeneration," Surv Ophthalmol. Mar.-Apr. 2006;51(2):137-52.
Edelhauser, H et al. "Ophthalmic Drug Delivery Systems for the Treatment of Retinal Diseases Basic Research to Clinical Applications." Investigative Ophthalmology & Visual Science, Nov. 2010. vol. 51, No. 11. pp. 5403-5420.
European Medicine Agency, Scientific Discussion; retrieved from the Internet; <http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000715/WC500043550.pdf>, EMEA 2007, 54 pages total. 2007.
Funatsu et al. "Association of vitreous inflammatory factors with diabetic macular edema," Ophthalmology 2009;116:73-79.
Gaudreault et al., "Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration," Investigative Ophthalmology and Visual Science. 2005;46:726-733. Retrieved from the Internet: <<http://www.iovs.org/cgi/reprint/46/2/726>>.
Gillies et al., "Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial," Ophthalmology. Sep. 2006;113(9):1533-1538.
Hastedt & Wright, "Diffusion in porous materials above the percolation threshold," Pharm. Res. Sep. 1990; 7(9):893-901 (1990).
Heier et al, "Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema," Ophthalmology. Nov. 2000;107(11):2034-2038 ;discussion 2039.
Jena et al., "A Novel Technique for Surface Area and Particle Size Determination of Components of Fuel Cells and Batteries," Porous Materials, Inc., Dec. 2006, 3 pages total. Downloaded from the Internet: <<http://www.pmiapp.com/publications/docs/A_Novel_technique_for_surface_area.pdf>>.
Kang et al., "Inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity," Biol Pharm Bull. Jun. 2001;24(6):701-703.
Lopez-Armada et al., "Modulation of cell recruitment by anti-inflammatory agents in antigen-induced arthritis," Ann Rheum Dis Nov. 2002;61(11):1027-1030.
Luncentis, INN-Ranibizumab, "Scientific Discussion," European Medicines Agency ; retrieved from the Internet<http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_ Assessment_Report_-_Variation/human/000715/WC500101009.pdf>. Oct. 21, 2010. 32 pages.
Metal Powder Industries Federation, Porous Metal Design Guidebook, 2007, 24 pages total. Downloaded from the Internet: <<http://www.mpif.org/DesignCenter/porous.pdf>>.
MOTT Corporation, "Sintered Metal Powder Media," American Filtration & Separation Society 2007, 2 pages total. Downloaded from the Internet:<<http://www.afssociety.org/education/0907oneminute.htm>>.
Navarro, "The Optical Design of the Human Eye: a Critical Review," J Optom, Jan.-Mar. 2009 2(1): 3-18.
Okabe et al., "Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device," Investigative Ophthalmology and Visual Science. 2003;44:2702-2707. Downloaded from the Internet: <<http://www.iovs.org/cgi/reprint/44/6/2702>>.
PCT/US2015/059990, Nov. 10, 2015, WO 2016/077371.
PCT/US2016/062944, Nov. 18, 2016, WO 2017/087902.
PCT/US2017/026151, Apr. 5, 2017, WO 2017/176886.
Rosenfeld, "The Latest Research: Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy," Review of Ophthalmology's Retina Online, Feb. 2006; retrieved from the Internet: http://www.revophth.com/archive/newsletter/0206_retina.htm. 2 pages.
Smith et al., "Spectrophotometric determination of pKa values for fluorescein using activity coefficient corrections," WaterSA 2002; 28(4):395-402.
Soheilian et al., "Pilot Study of Intravitreal Injection of Diclofenac for Treatment of Macular Edema of Various Etiologies," Retina, Mar. 2010; 30(3): 509-515.
Theodossiadis et al., "Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration," Am J Ophthalmol. May 2009;147(5):825-830.
U.S. Appl. No. 13/615,229, filed Sep. 13, 2012, 2013/0165860.
U.S. Appl. No. 13/814,466, filed Jun. 28, 2013, 2013/0274691.
U.S. Appl. No. 13/814,470, filed Jun. 19, 2013, 2013/0274692.
U.S. Appl. No. 13/849,445, filed Mar. 22, 2013, 2013/0218081.
U.S. Appl. No. 13/988,298, filed Oct. 14, 2013, 2014/0031769.
U.S. Appl. No. 14/129,200, filed Dec. 24, 2013, 2014/0221941.
U.S. Appl. No. 14/212,817, filed Mar. 14, 2014, 2014/0276482.
U.S. Appl. No. 14/236,863, filed Aug. 8, 2014, 2014/0358125.
U.S. Appl. No. 14/376,331, filed Aug. 1, 2014, 2015/0080846.
U.S. Appl. No. 14/713,505, filed May 15, 2015, 2015/0250647.
U.S. Appl. No. 14/753,574, filed Jun. 29, 2015, 2015/0297402.
U.S. Appl. No. 14/937,754, filed Nov. 10, 2015, 2016/0128867.
U.S. Appl. No. 14/973,311, filed Dec. 17, 2015, 2016/0101046.
U.S. Appl. No. 15/060,467, filed Mar. 3, 2016, 2016/0258855.
U.S. Appl. No. 15/102,191, filed Jun. 6, 2016, 2016/0302965.
U.S. Appl. No. 15/270,493, filed Sep. 20, 2016, 2017/0071938.
U.S. Appl. No. 15/386,586, filed Dec. 21, 2016, 2017-0165110.
U.S. Appl. No. 15/606,647, filed May 26, 2017, 2017-0258634.
U.S. Appl. No. 15/730,537, filed Oct. 11, 2017, 2018-0243131.
U.S. Appl. No. 15/807,396, filed Nov. 8, 2017, 2018-0292403.
U.S. Appl. No. 15/840,965, filed Dec. 13, 2017, 2018-0161202.
U.S. Appl. No. 15/877,146, filed Jan. 22, 2018, 2018-0243130.
U.S. Appl. No. 15/880,180, filed Jan. 25, 2018, 2018-0147204.
U.S. Appl. No. 16/004,085, filed Jun. 8, 2018, 2018-0289542.
Williams et al., "Treating Diabetic Macular Edema With Ocular NSAIDs," Retinal Physician, Nov. 2007; retrieved from the Internet Nov. 11, 2007. http://www.retinalphysician.com/article.aspx?article=101096>, 5 pages total.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022098825A1 (fr) 2020-11-04 2022-05-12 Aerie Pharmaceuticals, Inc. Implant intraoculaire pour administration de médicament

Also Published As

Publication number Publication date
US20170165108A1 (en) 2017-06-15
MY182497A (en) 2021-01-25
US20190350754A1 (en) 2019-11-21
CA2955186C (fr) 2023-08-29
US11337853B2 (en) 2022-05-24
NZ728374A (en) 2021-02-26
EP3169289A1 (fr) 2017-05-24
RU2695563C2 (ru) 2019-07-24
CN106687079B (zh) 2019-10-11
RU2017104650A3 (fr) 2019-02-18
WO2016011191A1 (fr) 2016-01-21
BR112017000774B1 (pt) 2021-12-14
EP3679908A1 (fr) 2020-07-15
MX2017000609A (es) 2017-04-27
EP3169289B1 (fr) 2020-04-15
KR20170034396A (ko) 2017-03-28
CN106687079A (zh) 2017-05-17
IL250079B (en) 2021-08-31
IL250079A0 (en) 2017-03-30
AU2015289625B2 (en) 2019-10-10
JP6581194B2 (ja) 2019-09-25
BR112017000774A2 (pt) 2017-11-28
KR102416726B1 (ko) 2022-07-05
ES2803102T3 (es) 2021-01-22
CA2955186A1 (fr) 2016-01-21
AU2015289625A1 (en) 2017-02-02
EP3169289A4 (fr) 2018-03-07
JP2017521219A (ja) 2017-08-03
US20220378609A1 (en) 2022-12-01
ZA201700387B (en) 2019-12-18
RU2017104650A (ru) 2018-08-15

Similar Documents

Publication Publication Date Title
US11337853B2 (en) Ocular implant delivery device and method
US11666456B2 (en) Bone graft delivery loading assembly
TWI401099B (zh) 具可縮回的插管之流體流動控制裝置
EP1608428B1 (fr) Dispositif d&#39;implantation
RU2361628C2 (ru) Аппликатор для введения имплантата
NO325505B1 (no) Apparat for implantering av et okulaert implantat
TW201235064A (en) Apparatus and methods for delivering fluid and material to a subject
JP2001526945A (ja) 皮下インプラント用移植装置
CN112165964B (zh) 用于输出至少一种物质的输出设备和方法
US20170290985A1 (en) Revolving multi-cartridge hypodermic syringe and method of use
EP3398524B1 (fr) Unité de chargement d&#39;aiguille pour appareil de suture chirurgical
JP2018507066A (ja) 移植片アプリケータと移植片投与方法
NZ728374B2 (en) Ocular implant delivery device and method
JP7284144B2 (ja) 歯科用ディスペンサ
EP4114305B1 (fr) Emballage pour retenir et distribuer un ensemble tige d&#39;administration pour l&#39;administration d&#39;un implant
WO2017019631A1 (fr) Applicateur sous-cutané
WO2023102155A1 (fr) Dispositif d&#39;insertion sous-cutanée de milieux solides
JP5597199B2 (ja) 患者などの体内に液体を注入するための装置
AU2022257597A1 (en) Implant delivery device

Legal Events

Date Code Title Description
AS Assignment

Owner name: PHILLIPS PLASTICS CORPORATION, WISCONSIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BIANCHI, KEITH;HARTSIG, BILL;SPONSEL, MARK;SIGNING DATES FROM 20150617 TO 20150618;REEL/FRAME:041158/0131

Owner name: GENENTECH, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NUNN, SCOTT;PATEL, MUKUND;VEDRINE, LIONEL;AND OTHERS;SIGNING DATES FROM 20150427 TO 20150428;REEL/FRAME:041157/0404

Owner name: GENENTECH, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PHILLIPS PLASTICS CORPORATION;REEL/FRAME:041164/0592

Effective date: 20150624

Owner name: FORSIGHT VISION4, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GENENTECH, INC.;REEL/FRAME:041164/0672

Effective date: 20150709

AS Assignment

Owner name: GENENTECH, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PHILLIPS PLASTICS CORPORATION;REEL/FRAME:040954/0809

Effective date: 20150624

Owner name: PHILLIPS PLASTICS CORPORATION, WISCONSIN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BIANCHI, KEITH;HARTSIG, BILL;SPONSEL, MARK;SIGNING DATES FROM 20150617 TO 20150618;REEL/FRAME:040954/0707

Owner name: GENENTECH, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NUNN, SCOTT;PATEL, MUKUND;VEDRINE, LIONEL;AND OTHERS;SIGNING DATES FROM 20150427 TO 20150428;REEL/FRAME:040954/0918

Owner name: FORSIGHT VISION4, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GENENTECH, INC.;REEL/FRAME:040954/0957

Effective date: 20150709

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4